<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5145148</article-id><article-id pub-id-type="pmid">27930669</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0165109</article-id><article-id pub-id-type="publisher-id">PONE-D-16-18679</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Physiology</subject><subj-group><subject>Cell Fusion</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Types</subject><subj-group><subject>Fusion Genes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Growth Factors</subject><subj-group><subject>Fibroblast Growth Factor</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Growth Factors</subject><subj-group><subject>Fibroblast Growth Factor</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Endocrine Physiology</subject><subj-group><subject>Growth Factors</subject><subj-group><subject>Fibroblast Growth Factor</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject><subj-group><subject>Reverse Transcriptase-Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject><subj-group><subject>Reverse Transcriptase-Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Sequencing techniques</subject><subj-group><subject>RNA sequencing</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Sequencing techniques</subject><subj-group><subject>RNA sequencing</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Identification and Analysis</subject><subj-group><subject>Mutation Detection</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>RNA</subject><subj-group><subject>Messenger RNA</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="50204" pm="."><plain>Development of RNA-FISH Assay for Detection of Oncogenic <italic>FGFR3-TACC3</italic> Fusion Genes in FFPE Samples </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">RNA-FISH Assay for <italic>FGFR3-TACC3</italic> Fusion Genes Detection from FFPE Samples</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5819-523X</contrib-id><name><surname>Kurobe</surname><given-names>Masahiro</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kojima</surname><given-names>Takahiro</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nishimura</surname><given-names>Kouichi</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kandori</surname><given-names>Shuya</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kawahara</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yoshino</surname><given-names>Takayuki</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ueno</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Iizumi</surname><given-names>Yuichi</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mitsuzuka</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arai</surname><given-names>Yoichi</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tsuruta</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Habuchi</surname><given-names>Tomonori</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kobayashi</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Matsui</surname><given-names>Yoshiyuki</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ogawa</surname><given-names>Osamu</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sugimoto</surname><given-names>Mikio</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kakehi</surname><given-names>Yoshiyuki</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nagumo</surname><given-names>Yoshiyuki</given-names></name><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tsutsumi</surname><given-names>Masakazu</given-names></name><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Oikawa</surname><given-names>Takehiro</given-names></name><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kikuchi</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nishiyama</surname><given-names>Hiroyuki</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Astellas Pharma Inc., Tsukuba, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Tsukuba Clinical Research and Development Organization (T-CReDO), Faculty of Medicine, University of Tsukuba, Tsukuba, Japan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Urology, Graduate School of Medicine, Tohoku University, Sendai, Japan</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Urology, Graduate School of Medicine, Akita University, Akita, Japan</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Department of Urology, Hitachi General Hospital, Hitachi, Japan</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Department of Urology, Tsukuba Medical Center Hospital, Tsukuba, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Sapino</surname><given-names>Anna</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Universita degli Studi di Torino, ITALY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="50205" pm="."><plain><bold>Competing Interests: </bold>I have read the journal's policy and the authors of this manuscript have the following competing interests. </plain></SENT>
<SENT sid="50206" pm="."><plain>One co-author, Kouichi Nishimura, is currently a full-time employee at Astellas. </plain></SENT>
<SENT sid="50207" pm="."><plain>This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. </plain></SENT>
<SENT sid="50208" pm="."><plain>All remaining authors have declared no competing interests. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="50209" pm="."><plain><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> MK T. </plain></SENT>
<SENT sid="50210" pm="."><plain>Kojima KN HN.</p></list-item><list-item><p><bold>Data curation:</bold> MK T. </plain></SENT>
<SENT sid="50211" pm="."><plain>Kojima SU HN.</p></list-item><list-item><p><bold>Formal analysis:</bold> MK T. </plain></SENT>
<SENT sid="50212" pm="."><plain>Kojima KN HN.</p></list-item><list-item><p><bold>Investigation:</bold> MK T. </plain></SENT>
<SENT sid="50213" pm="."><plain>Kojima KN HN.</p></list-item><list-item><p><bold>Methodology:</bold> MK T. </plain></SENT>
<SENT sid="50214" pm="."><plain>Kojima KN SU HN.</p></list-item><list-item><p><bold>Project administration:</bold> MK T. </plain></SENT>
<SENT sid="50215" pm="."><plain>Kojima KN SU HN.</p></list-item><list-item><p><bold>Resources:</bold> MK T. </plain></SENT>
<SENT sid="50216" pm="."><plain>Kojima KN SK T. </plain></SENT>
<SENT sid="50217" pm="."><plain>Kawahara TY SU YI KM YA HT TH T. </plain></SENT>
<SENT sid="50218" pm="."><plain>Kobayashi YM OO MS YK YN MT TO KK HN.</p></list-item><list-item><p><bold>Supervision:</bold> HN.</p></list-item><list-item><p><bold>Writing – original draft:</bold> MK T. </plain></SENT>
<SENT sid="50219" pm="."><plain>Kojima KN.</p></list-item><list-item><p><bold>Writing – review &amp; editing:</bold> MK T. </plain></SENT>
<SENT sid="50220" pm="."><plain>Kojima KN SK T. </plain></SENT>
<SENT sid="50221" pm="."><plain>Kawahara TY SU YI KM YA HT TH T. </plain></SENT>
<SENT sid="50222" pm="."><plain>Kobayashi YM OO MS YK YN MT TO KK HN.</p></list-item></list> </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>nishiuro@md.tsukuba.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>8</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>12</issue><elocation-id>e0165109</elocation-id><history><date date-type="received"><day>15</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>6</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 Kurobe et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Kurobe et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0165109.pdf"/><abstract><sec id="sec001"><title><text><SENT sid="50223" pm="."><plain>Introduction and Objectives </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="50224" pm="."><plain>Oncogenic <italic>FGFR3-TACC3</italic> fusions and <italic>FGFR3</italic> mutations are target candidates for small molecule inhibitors in bladder cancer (BC). </plain></SENT>
<SENT sid="50225" pm="."><plain>Because <italic>FGFR3</italic> and <italic>TACC3</italic> genes are located very closely on chromosome 4p16.3, detection of the fusion by DNA-FISH (fluorescent in situ hybridization) is not a feasible option. </plain></SENT>
<SENT sid="50226" pm="."><plain>In this study, we developed a novel RNA-FISH assay using branched DNA probe to detect <italic>FGFR3-TACC3</italic> fusions in formaldehyde-fixed paraffin-embedded (FFPE) human BC samples. </plain></SENT>
</text></SecTag></p></sec><sec id="sec002"><title><text><SENT sid="50227" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="50228" pm="."><plain>The RNA-FISH assay was developed and validated using a mouse xenograft model with human BC cell lines. </plain></SENT>
<SENT sid="50229" pm="."><plain>Next, we assessed the consistency of the RNA-FISH assay using 104 human BC samples. </plain></SENT>
<SENT sid="50230" pm="."><plain>In this study, primary BC tissues were stored as frozen and FFPE tissues. <italic>FGFR3-TACC3</italic> fusions were independently detected in FFPE sections by the RNA-FISH assay and in frozen tissues by RT-PCR. </plain></SENT>
<SENT sid="50231" pm="."><plain>We also analyzed the presence of <italic>FGFR3</italic> mutations by targeted sequencing of genomic DNA extracted from deparaffinized FFPE sections. </plain></SENT>
</text></SecTag></p></sec><sec id="sec003"><title><text><SENT sid="50232" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="50233" pm="."><plain><italic>FGFR3-TACC3</italic> fusion transcripts were identified by RNA-FISH and RT-PCR in mouse xenograft FFPE tissues using the human BC cell lines RT112 and RT4. </plain></SENT>
<SENT sid="50234" pm="."><plain>These cell lines have been reported to be fusion-positive. </plain></SENT>
<SENT sid="50235" pm="."><plain>Signals for <italic>FGFR3-TACC3</italic> fusions by RNA-FISH were positive in 2/60 (3%) of non-muscle-invasive BC (NMIBC) and 2/44 (5%) muscle-invasive BC (MIBC) patients. </plain></SENT>
<SENT sid="50236" pm="."><plain>The results of RT-PCR of all 104 patients were identical to those of RNA-FISH. <italic>FGFR3</italic> mutations were detected in 27/60 (45%) NMIBC and 8/44 (18%) MIBC patients. </plain></SENT>
<SENT sid="50237" pm="."><plain>Except for one NMIBC patient, <italic>FGFR3</italic> mutation and <italic>FGFR3-TACC3</italic> fusion were mutually exclusive. </plain></SENT>
</text></SecTag></p></sec><sec id="sec004"><title><text><SENT sid="50238" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="50239" pm="."><plain>We developed an RNA-FISH assay for detection of the <italic>FGFR3-TACC3</italic> fusion in FFPE samples of human BC tissues. </plain></SENT>
<SENT sid="50240" pm="."><plain>Screening for not only <italic>FGFR3</italic> mutations, but also for <italic>FGFR3-TACC3</italic> fusion transcripts has the potential to identify additional patients that can be treated with FGFR inhibitors. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>Challenging Exploratory Research: 26670696</award-id><principal-award-recipient><name><surname>Nishiyama</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>B: 26293349</award-id><principal-award-recipient><name><surname>Nishiyama</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><funding-statement>The study was funded by Astellas (H.N.), and designed and analyzed by the authors in collaboration with Astellas. Astellas had a role in the design and conduct of the study; management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript. This work was also supported in part by a Grant-in-Aid for Challenging Exploratory Research (H.N.) (grant number 26670696) and a Grant-in-Aid for Scientific Research B (H.N.) (grant number 26293349) from the Japan Society for the Promotion of Science (JSPS) (<ext-link ext-link-type="uri" xlink:href="https://www.jsps.go.jp/english/">https://www.jsps.go.jp/english/</ext-link>). The JSPS had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="8"/><table-count count="1"/><page-count count="19"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec005"><title><text><SENT sid="50241" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="50242" pm="."><plain>Activation of <italic>fibroblast growth factor receptor 3</italic> (<italic>FGFR3</italic>) has been reported to play important roles in several malignancies, including uterine cervix carcinoma and multiple myeloma as well as bladder cancers (BC)[<xref rid="pone.0165109.ref001" ref-type="bibr">1</xref>][<xref rid="pone.0165109.ref002" ref-type="bibr">2</xref>]. </plain></SENT>
<SENT sid="50243" pm="."><plain>Ninety-seven percent of activating <italic>FGFR3</italic> mutations observed in BC are clustered in either exon 7 (codons 248 and 249), exon 10 (codons 372, 373 and 375), or exon 15 (codon 652)[<xref rid="pone.0165109.ref003" ref-type="bibr">3</xref>]. </plain></SENT>
<SENT sid="50244" pm="."><plain>Mutations in exons 7 or 10 create unpaired cysteines in the proximal extracellular region, leading to the formation of disulfide bonds between adjacent receptors, thereby inducing ligand-independent dimerization and activation[<xref rid="pone.0165109.ref004" ref-type="bibr">4</xref>][<xref rid="pone.0165109.ref005" ref-type="bibr">5</xref>]. </plain></SENT>
<SENT sid="50245" pm="."><plain>Mutations within the kinase domain, such as codon 652, are thought to induce a conformational change in the activation loop, resulting in constitutive autophosphorylation of the receptor[<xref rid="pone.0165109.ref006" ref-type="bibr">6</xref>]. </plain></SENT>
</text></p><p><text><SENT sid="50246" pm="."><plain>Recently, <italic>FGFR3-transforming acidic coiled-coil 3</italic> (<italic>TACC3</italic>) fusions have been identified in glioblastoma[<xref rid="pone.0165109.ref007" ref-type="bibr">7</xref>], head and neck carcinoma[<xref rid="pone.0165109.ref008" ref-type="bibr">8</xref>], and lung cancer[<xref rid="pone.0165109.ref009" ref-type="bibr">9</xref>], as well as urothelial cancer (UC)[<xref rid="pone.0165109.ref010" ref-type="bibr">10</xref>]. </plain></SENT>
<SENT sid="50247" pm="."><plain>FGFR tyrosine kinase inhibitors have been developed and shown to be effective in cell lines harboring not only an activating <italic>FGFR3</italic> mutations, but also an <italic>FGFR3-TACC3</italic> fusion gene in vitro and in vivo[<xref rid="pone.0165109.ref011" ref-type="bibr">11</xref>]. </plain></SENT>
<SENT sid="50248" pm="."><plain>These include the S249C mutation in human BC cells 97–7[<xref rid="pone.0165109.ref012" ref-type="bibr">12</xref>], Y375C mutation in human BC cells MGH-U3[<xref rid="pone.0165109.ref013" ref-type="bibr">13</xref>], and <italic>FGFR3-TACC3</italic> fusion in human glioma stem cells GIC-1123[<xref rid="pone.0165109.ref011" ref-type="bibr">11</xref>]. </plain></SENT>
<SENT sid="50249" pm="."><plain>In addition, significant clinical responses to an FGFR inhibitor were reported in <italic>FGFR3-TACC3</italic> fusion-positive patients with cervical cancer[<xref rid="pone.0165109.ref014" ref-type="bibr">14</xref>] or glioma[<xref rid="pone.0165109.ref011" ref-type="bibr">11</xref>] in Phase I clinical trials. </plain></SENT>
<SENT sid="50250" pm="."><plain>Thus, detection of not only the activating <italic>FGFR3</italic> mutations, especially in exons 7, 10 and 15, but also the <italic>FGFR3-TACC3</italic> fusion in BC patients could be clinically important to identify responders to FGFR kinase inhibitors. </plain></SENT>
</text></p><p><text><SENT sid="50251" pm="."><plain>DNA fluorescent in situ hybridization (DNA-FISH) is widely used to detect fusion genes from genomic DNA[<xref rid="pone.0165109.ref015" ref-type="bibr">15</xref>][<xref rid="pone.0165109.ref016" ref-type="bibr">16</xref>]. </plain></SENT>
<SENT sid="50252" pm="."><plain>However, genomic DNA-FISH is not a feasible option to detect an <italic>FGFR3-TACC3</italic> fusion. </plain></SENT>
<SENT sid="50253" pm="."><plain>Generally, fusion detection assays of DNA-FISH are based on 2 strategies, dual fusion or break apart. </plain></SENT>
<SENT sid="50254" pm="."><plain>In the dual fusion strategy, 2 colored probes are designed to span the breakpoint of the 2 genes involved in the fusion. </plain></SENT>
<SENT sid="50255" pm="."><plain>These probes are visually distinct in normal cells but appear merged by the specific fusion event. </plain></SENT>
<SENT sid="50256" pm="."><plain>However, this strategy is not a feasible option for <italic>FGFR3-TACC3</italic> fusion detection because the 2 genes map very closely, at a distance of only 48 Kb on chromosome 4p16.3, and thus the 2 probes appear merged in both normal cells and fusion-positive cells. </plain></SENT>
<SENT sid="50257" pm="."><plain>In the break-apart strategy, probes are designed to target opposite sides of the translocation break point for a given gene, each labeled by a different color. </plain></SENT>
<SENT sid="50258" pm="."><plain>These probes generate signals in normal cells that are co-localized and appear merged. </plain></SENT>
<SENT sid="50259" pm="."><plain>Following a translocation, the signals are no longer co-localized but appear to be separate. </plain></SENT>
<SENT sid="50260" pm="."><plain>This strategy is also not a feasible option for <italic>FGFR3-TACC3</italic> fusion detection. </plain></SENT>
<SENT sid="50261" pm="."><plain>According to Parker et al., the <italic>FGFR3-TACC3</italic> fusion is caused by tandem duplication of a 70 kb region on 4p16.3[<xref rid="pone.0165109.ref017" ref-type="bibr">17</xref>]. </plain></SENT>
<SENT sid="50262" pm="."><plain>This is confirmed by performing genomic DNA capillary sequencing of tandem duplication boundaries[<xref rid="pone.0165109.ref017" ref-type="bibr">17</xref>]. </plain></SENT>
<SENT sid="50263" pm="."><plain>Therefore, fluorescent probes appear merged in both normal and fusion-positive cells. </plain></SENT>
</text></p><p><text><SENT sid="50264" pm="."><plain>Recently, several RNA-ISH based assays have been applied to detect mRNA transcripts of fusion genes, which include padlock probes/rolling circle amplification (RCA), “smFISH,” and “branched DNA (bDNA)-FISH”. </plain></SENT>
<SENT sid="50265" pm="."><plain>For example, <italic>TMPRSS2-ERG</italic> fusion transcripts were identified by padlock probes/RCA[<xref rid="pone.0165109.ref018" ref-type="bibr">18</xref>]. </plain></SENT>
<SENT sid="50266" pm="."><plain>However, the padlock probe/RCA approach needs an in situ cDNA preparation, which would pose additional technical difficulty when using formaldehyde-fixed paraffin-embedded (FFPE) tissue slides due to degradation and modification of nucleic acids. “smFISH” systems using single fluorophore-labeled probes are also applied to detect mRNA transcripts of fusion genes[<xref rid="pone.0165109.ref019" ref-type="bibr">19</xref>][<xref rid="pone.0165109.ref020" ref-type="bibr">20</xref>]. </plain></SENT>
<SENT sid="50267" pm="."><plain>Following smFISH, “bDNA-FISH” system has been applied to detect mRNA transcripts of fusion genes[<xref rid="pone.0165109.ref021" ref-type="bibr">21</xref>]. </plain></SENT>
<SENT sid="50268" pm="."><plain>In “bDNA-FISH,” sequential hybridization of a series of oligonucleotide probes generates signal amplification. </plain></SENT>
<SENT sid="50269" pm="."><plain>This contrasts with “smFISH,” which lacks a signal-amplification step. </plain></SENT>
<SENT sid="50270" pm="."><plain>The bDNA probes are commercially available as a 'ViewRNA' system (Affymetrix, Santa Clara, CA, USA) or an 'RNAscope' system (Advanced Cell Diagnostics, Hayward, CA, USA). “bDNA-FISH” and “smFISH” demonstrate the same accuracy, but “bDNA-FISH” yields brighter spots with a better signal-to-noise ratio[<xref rid="pone.0165109.ref022" ref-type="bibr">22</xref>]. </plain></SENT>
<SENT sid="50271" pm="."><plain>Neither “smFISH” nor “bDNA-FISH” assay has been applied to detect <italic>FGFR3-TACC3</italic> fusion yet. </plain></SENT>
</text></p><p><text><SENT sid="50272" pm="."><plain>Here, we sought to develop an RNA-FISH assay using bDNA probes to detect <italic>FGFR3-TACC3</italic> fusion gene transcripts in FFPE tissue, which are the most widely available specimens in clinical settings. </plain></SENT>
<SENT sid="50273" pm="."><plain>In this study, we first applied an RNA-FISH assay using bDNA probes to detect <italic>FGFR3-TACC3</italic> fusion transcripts in human FFPE BC tissue. </plain></SENT>
<SENT sid="50274" pm="."><plain>We also analyzed the relationship between the <italic>FGFR3</italic> mutation, <italic>FGFR3-TACC3</italic> fusion status, and clinical information in a prospective multicenter cohort of more than 100 patients with the clinical diagnosis of BC. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec006"><title><text><SENT sid="50275" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec007"><title><text><SENT sid="50276" pm="."><plain>Patients and tissue samples </plain></SENT>
</text></title><p><text><SENT sid="50277" pm="."><plain>This study was conducted as a prospective multicenter cohort study including 144 patients from 7 institutions with the clinical diagnosis of UC. </plain></SENT>
<SENT sid="50278" pm="."><plain>The participating hospitals were Tohoku University Hospital, Akita University Hospital, Kyoto University Hospital, Kagawa University Hospital, Hitachi General Hospital, Tsukuba Medical Center Hospital, and Tsukuba University Hospital. </plain></SENT>
<SENT sid="50279" pm="."><plain>Primary cancer tissue samples obtained from 106 patients with non-metastatic BCs were stored as frozen and FFPE tissues. </plain></SENT>
<SENT sid="50280" pm="."><plain>The remaining 38 cases were metastatic UC includes bladder, ureter, and renal pelvis cancer. </plain></SENT>
<SENT sid="50281" pm="."><plain>For these metastatic UC patients, archival FFPE samples of the primary tumors were used if fresh frozen tissues were not available. </plain></SENT>
</text></p><p><text><SENT sid="50282" pm="."><plain>This research protocol was approved by the Ethics Committee of Tsukuba University Hospital (Approval number: H25-116). </plain></SENT>
<SENT sid="50283" pm="."><plain>This study was also reviewed and approved by the Ethics Committees of the following institutes: Tohoku University Hospital, Akita University Hospital, Kyoto University Hospital, Kagawa University Hospital, Hitachi General Hospital, and Tsukuba Medical Center Hospital. </plain></SENT>
<SENT sid="50284" pm="."><plain>Tumor specimens, blood, and clinicopathologic information were collected with written informed consent. </plain></SENT>
</text></p><p><text><SENT sid="50285" pm="."><plain>Portions of tissue samples were frozen and stored at −80°C, and the remainder of the sample was fixed in 10% formaldehyde for 12–24 hours at room temperature and embedded in paraffin for diagnostic assessment. </plain></SENT>
<SENT sid="50286" pm="."><plain>Hematoxylin and eosin staining (H&amp;E) was performed, and the slides were reviewed by a pathologist. </plain></SENT>
<SENT sid="50287" pm="."><plain>Tumors were staged according to the 2009 UICC 7th TNM Classification system. </plain></SENT>
<SENT sid="50288" pm="."><plain>Tissue sections that showed malignant tumor cell nuclei in 10% or more cells on the whole specimen were included in this study. </plain></SENT>
<SENT sid="50289" pm="."><plain>A total of 144 patients were enrolled, 7 patients were excluded from this study due to a low tumor fraction in the whole specimen (less than 10%). </plain></SENT>
<SENT sid="50290" pm="."><plain>Two patients were excluded because their tumors were not malignant. </plain></SENT>
<SENT sid="50291" pm="."><plain>One sample was excluded due to a lack of genomic DNA yield from the FFPE sample. </plain></SENT>
<SENT sid="50292" pm="."><plain>Thirty samples were excluded because fresh frozen tissues were not available. </plain></SENT>
<SENT sid="50293" pm="."><plain>Finally, 104 BC patients were included. </plain></SENT>
<SENT sid="50294" pm="."><plain>The patient characteristics are summarized in <xref rid="pone.0165109.t001" ref-type="table">Table 1</xref>. </plain></SENT>
<SENT sid="50295" pm="."><plain>Of the 104 patients, 60 were classified as non-muscle invasive BC (NMIBC) and 44 as muscle-invasive BC (MIBC) according to the pathological findings. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0165109.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165109.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="50296" pm="."><plain>Characteristics of bladder cancer patients </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0165109.t001g" xlink:href="pone.0165109.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><th align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><th align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50297" pm="."><plain>NMIBC </plain></SENT>
</text></th><th align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50298" pm="."><plain>MIBC </plain></SENT>
</text></th><th align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50299" pm="."><plain>Total </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50300" pm="."><plain>N </plain></SENT>
</text></td><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50301" pm="."><plain>60 </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50302" pm="."><plain>44 </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50303" pm="."><plain>104 </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50304" pm="."><plain>Age (years) </plain></SENT>
</text></td><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50305" pm="."><plain>Median (range) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50306" pm="."><plain>69 (30–87) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50307" pm="."><plain>72 (42–87) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50308" pm="."><plain>70 (30–87) </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50309" pm="."><plain>Gender </plain></SENT>
</text></td><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50310" pm="."><plain>Male (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50311" pm="."><plain>55 (92) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50312" pm="."><plain>32 (73) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50313" pm="."><plain>87 (84) </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50314" pm="."><plain>Female (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50315" pm="."><plain>5 (8) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50316" pm="."><plain>12 (27) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50317" pm="."><plain>17 (16) </plain></SENT>
</text></td></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50318" pm="."><plain>T stage </plain></SENT>
</text></td><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50319" pm="."><plain>Ta (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50320" pm="."><plain>43 (72) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50321" pm="."><plain>Tis/T1 (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50322" pm="."><plain>17 (28) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50323" pm="."><plain>≧T2 (%) </plain></SENT>
</text></td><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50324" pm="."><plain>44 (100) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50325" pm="."><plain>M stage </plain></SENT>
</text></td><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50326" pm="."><plain>M1 (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50327" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50328" pm="."><plain>4 (10) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50329" pm="."><plain>Grade </plain></SENT>
</text></td><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50330" pm="."><plain>High grade (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50331" pm="."><plain>26 (47) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50332" pm="."><plain>Low grade (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50333" pm="."><plain>34 (53) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50334" pm="."><plain>Multiplicity </plain></SENT>
</text></td><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50335" pm="."><plain>Solitary (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50336" pm="."><plain>24 (40) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50337" pm="."><plain>23 (52) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50338" pm="."><plain>Multiple (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50339" pm="."><plain>33 (55) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50340" pm="."><plain>15 (34) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50341" pm="."><plain>Unknown (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50342" pm="."><plain>3 (5) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50343" pm="."><plain>6 (14) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50344" pm="."><plain>Tumor size </plain></SENT>
</text></td><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50345" pm="."><plain>&lt;3 cm (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50346" pm="."><plain>41 (68) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50347" pm="."><plain>9 (20) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"/><td align="left" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50348" pm="."><plain>&gt;3 cm (%) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50349" pm="."><plain>19 (32) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"><text><SENT sid="50350" pm="."><plain>35 (80) </plain></SENT>
</text></td><td align="center" style="background-color:#E9EDF4" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></SecTag></sec><sec id="sec008"><title><text><SENT sid="50351" pm="."><plain>Cell lines and cell culture </plain></SENT>
</text></title><p><text><SENT sid="50352" pm="."><plain>Three human BC cell lines (RT112[<xref rid="pone.0165109.ref023" ref-type="bibr">23</xref>], <italic>FGFR3-TACC3</italic> fusion-positive[<xref rid="pone.0165109.ref010" ref-type="bibr">10</xref>]; RT4[<xref rid="pone.0165109.ref024" ref-type="bibr">24</xref>], <italic>FGFR3-TACC3</italic> fusion-positive[<xref rid="pone.0165109.ref010" ref-type="bibr">10</xref>]; and T24[<xref rid="pone.0165109.ref025" ref-type="bibr">25</xref>], <italic>FGFR3</italic> wild type[<xref rid="pone.0165109.ref010" ref-type="bibr">10</xref>]) and HSC-39 (human signet ring cell gastric carcinoma cell line[<xref rid="pone.0165109.ref026" ref-type="bibr">26</xref>], <italic>FGFR3</italic> wild type) were used. </plain></SENT>
<SENT sid="50353" pm="."><plain>All cells were cultured in RPMI 1640 (Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS) at 37°C in 5% CO2 and 20% O2. </plain></SENT>
</text></p></sec><sec id="sec009"><title><text><SENT sid="50354" pm="."><plain>Subcutaneous xenografts and FFPE slide preparation </plain></SENT>
</text></title><p><text><SENT sid="50355" pm="."><plain>For establishment of tumor xenografts, log-phase RT112, RT4, T24, and HSC-39 cells were implanted intradermally (5×10<sup>6</sup> cells per mouse in 0.1 mL PBS) into the backs of female BALB/c-nu/nu mice (Charles River Laboratories, Wilmington, MA, USA) at 5 to 6 weeks old. </plain></SENT>
<SENT sid="50356" pm="."><plain>All surgery was performed under ether anesthesia, and all efforts were made to minimize suffering. </plain></SENT>
<SENT sid="50357" pm="."><plain>Mice were euthanized by cervical dislocation while under anesthesia when tumor size exceeded 200 mm<sup>3</sup> in size. </plain></SENT>
<SENT sid="50358" pm="."><plain>Tumors were excised from mice and divided into 2 pieces. </plain></SENT>
<SENT sid="50359" pm="."><plain>One piece was dip-washed in saline, blotted dry, snap frozen in liquid nitrogen, and stored at −80°C until analysis. </plain></SENT>
<SENT sid="50360" pm="."><plain>The other piece was fixed in 10% formaldehyde for 24 hours at room temperature before embedding in paraffin for tissue sections. </plain></SENT>
<SENT sid="50361" pm="."><plain>All experiments were performed in compliance with the relevant Japanese and institutional laws and guidelines and approved by the University of Tsukuba Animal Ethics Committee (authorization number 15–162). </plain></SENT>
</text></p></sec><sec id="sec010"><title><text><SENT sid="50362" pm="."><plain>Detection of fusion transcripts by RNA-FISH </plain></SENT>
</text></title><p><text><SENT sid="50363" pm="."><plain>In situ detection of <italic>FGFR3</italic> and <italic>TACC3</italic> transcripts in FFPE sections was conducted using a QuantiGene® ViewRNA ISH Tissue Assay Kit (Affymetrix) with a modified protocol for custom-made probes. </plain></SENT>
<SENT sid="50364" pm="."><plain>For <italic>TACC3</italic>, Alexa 546 (Excitation = 556 nm and Emission = 573 nm) was used, and for <italic>FGFR3</italic>, Alexa 647 (Excitation = 650 nm and Emission = 668 nm) was used as a fluorescent dye; both were purchased as custom-made products (namely type 1 for <italic>TACC3</italic> and type 6 for <italic>FGFR3</italic>) from Veritas (an Affymetrix sales representative in Japan). </plain></SENT>
<SENT sid="50365" pm="."><plain>A step-by-step protocol is provided as the <xref ref-type="supplementary-material" rid="pone.0165109.s006">S1 Protocol</xref>. </plain></SENT>
<SENT sid="50366" pm="."><plain>In brief, FFPE sections were treated according to the manufacturer’s protocol of QuantiGene® ViewRNA ISH Tissue Assay Kit before adding the labeled probe solution. </plain></SENT>
<SENT sid="50367" pm="."><plain>In order to detect the mRNA signal with high resolution, the fluorescent label reagent (label probe mix) from a QuantiGene ViewRNA ISH Cell Assay Kit (Affymetrix) and its compatible custom-made probes described above were used. </plain></SENT>
</text></p><p><text><SENT sid="50368" pm="."><plain>The target sequence of the <italic>FGFR3</italic>-specific oligonucleotide probes was located in exons 3 to 11 corresponding to nucleotide numbers 395–1595 in the sequence of NM_000142.3 of <italic>FGFR3</italic> except for exons 8, 9 and 10, which are variable in alternative splicing. </plain></SENT>
<SENT sid="50369" pm="."><plain>Thus the probes specifically hybridize to all three variants of human <italic>FGFR3</italic> mRNA. </plain></SENT>
<SENT sid="50370" pm="."><plain>The target sequence of the <italic>TACC3</italic>-specific oligonucleotide probes was located in exons 12–16 corresponding to the nucleotide numbers 2200–2838 in the sequence of NM_006342.1 of <italic>TACC3</italic>. <xref ref-type="fig" rid="pone.0165109.g001">Fig 1</xref> shows a schematic representation of how <italic>FGFR3</italic>-specific probes and <italic>TACC3</italic>-specific probes were designed. </plain></SENT>
<SENT sid="50371" pm="."><plain>The probe sets for each gene consisted of around 15 to 20 pairs of probes. </plain></SENT>
<SENT sid="50372" pm="."><plain>One pair consisted of 2 of about 20 base oligonucleotide probes. </plain></SENT>
<SENT sid="50373" pm="."><plain>The 2 probe pairs are designed to hybridize to adjacent segments on the target RNA, allowing further hybridization of a preamplification probe (Affymetrix) for signal amplification by labeled probes. </plain></SENT>
<SENT sid="50374" pm="."><plain>This “double Z” structure assures the specificity to the target mRNA because this construction of a “double Z” structure by 2 adjacent probes is required for signal amplification. </plain></SENT>
<SENT sid="50375" pm="."><plain>A schematic figure explaining how this bDNA-FISH-based assay works is shown in <xref ref-type="fig" rid="pone.0165109.g002">Fig 2</xref>. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0165109.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165109.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="50376" pm="."><plain>Schematic representation of how <italic>FGFR3</italic>-specific probes and <italic>TACC3</italic>-specific probes were designed. </plain></SENT>
</text></title></caption><graphic xlink:href="pone.0165109.g001"/></fig></SecTag><SecTag type="FIG"><fig id="pone.0165109.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165109.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="50377" pm="."><plain>A schematic figure explaining how bDNA-FISH works. </plain></SENT>
</text></title></caption><graphic xlink:href="pone.0165109.g002"/></fig></SecTag><p><text><SENT sid="50378" pm="."><plain>After fluorescent label probe hybridization, slides were dried and mounted with ProLong® Gold Antifade Reagents (Thermo Fisher Scientific, Waltham, MA, USA). </plain></SENT>
<SENT sid="50379" pm="."><plain>Ten non-overlapping fields of view of fluorescent signal images per slide were obtained for each fluoresce with ×630-fold magnification with a confocal laser microscope (LSM700; Carl Zeiss, Zena, Germany). </plain></SENT>
<SENT sid="50380" pm="."><plain>For <italic>FGFR</italic>, a Cy5 (Excitation/Emission = 650/670 nm) filter was used, and for <italic>TACC3</italic>, a Cy3 (Excitation/Emission = 552/570 nm) filter was used. </plain></SENT>
<SENT sid="50381" pm="."><plain>Each field of view was obtained from a different part of the tissue portion in which cancer cells were present. </plain></SENT>
<SENT sid="50382" pm="."><plain>The presence of cancer cells was confirmed by comparing DAPI-stained nucleic images with H&amp;E stained images. </plain></SENT>
<SENT sid="50383" pm="."><plain>These images were analyzed using IN Cell Investigator Developer Toolbox 1.9.2 which is the image analysis software used with IN Cell Analyzer 2000 (GE Healthcare, Amersham, UK) to obtain the number of signals for each probe (<italic>FGFR3</italic> and <italic>TACC3</italic>) and to examine whether each signal dot from each probe overlapped or not. </plain></SENT>
<SENT sid="50384" pm="."><plain>Overlapped/co-localized dots were recognized as “overlapped/co-localized” when 50% of the area from each signal overlapped with another signal. </plain></SENT>
<SENT sid="50385" pm="."><plain>When overlapped/co-localized signals were observed, the number of such overlapped/co-localized dots were counted. </plain></SENT>
<SENT sid="50386" pm="."><plain>These image analyses were performed unbiasedly and automatically by software with a fixed protocol every time. </plain></SENT>
<SENT sid="50387" pm="."><plain>A schematic representation of how co-localized signals were detected by IN Cell Investigator is shown in <xref ref-type="supplementary-material" rid="pone.0165109.s002">S1 Fig</xref>. </plain></SENT>
<SENT sid="50388" pm="."><plain>The overlapped signals could be detected not only from real fusion mRNA, but also from proximity of the 2 target RNAs simply by chance. </plain></SENT>
<SENT sid="50389" pm="."><plain>Actually, a small number of overlapped signals were detected in the negative control HSC-39. </plain></SENT>
<SENT sid="50390" pm="."><plain>These accidentally overlapped signals could be increased in direct proportion to the total number of <italic>FGFR3</italic> signals and <italic>TACC3</italic> signals. </plain></SENT>
<SENT sid="50391" pm="."><plain>To overcome this problem, the number of overlapped signals was divided by the number of <italic>FGFR3</italic> and <italic>TACC3</italic> signals. </plain></SENT>
<SENT sid="50392" pm="."><plain>These processes were repeated for each 10 non-overlapping fields of view per one sample. </plain></SENT>
<SENT sid="50393" pm="."><plain>The co-localization ratios were defined as the ratio of the co-localized count number per total number for each probes, and this co-localization ratio for 10 non-overlapping fields in each slide was plotted as in a scatter diagram and used for detection of the presence of fusion transcripts. </plain></SENT>
</text></p></sec><sec id="sec011"><title><text><SENT sid="50394" pm="."><plain>RNA extraction and cDNA synthesis </plain></SENT>
</text></title><p><text><SENT sid="50395" pm="."><plain>Total RNA was extracted from frozen tissues using TRIzol (Thermo Fisher Scientific), and from FFPE tissues using an RNeasy FFPE kit (Qiagen, Hilden, Germany). </plain></SENT>
<SENT sid="50396" pm="."><plain>First strand cDNA was synthesized using Superscript Ⅲ Super Mix and oligo dT primers (Thermo Fisher Scientific) according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="50397" pm="."><plain>The quality of the cDNA from FFPE tissue was tested for the presence of the <italic>hypoxanthine guanine phosphoribosyltransferase</italic> (<italic>HPRT</italic>) housekeeping gene (152 bps amplified product; forward primer, 5’-GACTTTGCTTTCCTTGGTC-3’ and reverse primer, 5’-AGTCAAGGGCATATCCTAC-3’). </plain></SENT>
<SENT sid="50398" pm="."><plain>The quality of cDNA from frozen tissue was tested for the <italic>β-actin</italic> housekeeping gene (539 bps amplified product using forward primer 5’-GTGGGGCGCCCCAGGCACCA-3’ and reverse primer 5’-CTCCTTAATGTCACGCACGATTTC-3’). </plain></SENT>
</text></p></sec><sec id="sec012"><title><text><SENT sid="50399" pm="."><plain>Identification of <italic>FGFR3-TACC3</italic> fusion transcripts by RT-PCR and DNA sequencing </plain></SENT>
</text></title><p><text><SENT sid="50400" pm="."><plain>We designed a reverse transcription-PCR (RT-PCR) assay for the detection of all known and possible new variants of <italic>FGFR3-TACC3</italic> fusions that retain the mRNA sequences coding for the key FGFR-tyrosine kinase domain and transforming acidic coiled-coil domain required for oncogenic activity of the fusion protein. </plain></SENT>
<SENT sid="50401" pm="."><plain>Previously reported <italic>FGFR3-TACC3</italic> fusions were exons 18 or 19 of <italic>FGFR3</italic> and exons 4–13 of <italic>TACC3</italic>, and a short intron was inserted in some cases[<xref rid="pone.0165109.ref027" ref-type="bibr">27</xref>]. </plain></SENT>
<SENT sid="50402" pm="."><plain>To detect <italic>FGFR3-TACC3</italic> fusion gene transcripts, we performed RT-PCR using our original primers as follows: the forward primer, <italic>FGFR3</italic> exon2-Forward: 5’- CCTGAGGACGCCGCGGCCCCCGCCCCC-3’ and the reverse primer, <italic>TACC3</italic> exon16-Reverse: 5’-TGACCTCCACGGAGCCGCTGTCCCCGC-3’; amplification conditions were 94°C for 2 min (98°C for 5 sec/68°C for 3 min) for 40 cycles, then 72°C for 5 min. </plain></SENT>
<SENT sid="50403" pm="."><plain>PCR-amplified products were diluted 1:50 in sterile water, and then used for nested PCR amplifications with internal primers. </plain></SENT>
<SENT sid="50404" pm="."><plain>For the nested PCR, primer pairs were <italic>FGFR3</italic> exon 2-Forward: 5’- GCCATGGGCGCCCCTGCCTGCGCCCTC-3’ and <italic>TACC3</italic> exon 16-Reverse: 5’- GACCTCATCTCCAAGATGGAGAAGATC-3’. </plain></SENT>
<SENT sid="50405" pm="."><plain>A schematic representation of RT-PCR primer positions is shown in <xref ref-type="fig" rid="pone.0165109.g003">Fig 3A</xref>. </plain></SENT>
<SENT sid="50406" pm="."><plain>All designed primers were BLASTed against the human genome to make sure they were not complementary to other regions of the genome[<xref rid="pone.0165109.ref028" ref-type="bibr">28</xref>]. </plain></SENT>
<SENT sid="50407" pm="."><plain>After amplification of the fusion gene specific template by PCR, the finding was confirmed by agarose gel electrophoresis according to the expected length of the amplicon (RT112; 2850 bps and RT4; 4461 bps). </plain></SENT>
<SENT sid="50408" pm="."><plain>The PCR products obtained as described above were purified and sequenced by the Sanger method. </plain></SENT>
<SENT sid="50409" pm="."><plain>Conventional fluorescent dye chemistry sequencing was performed on an ABI Prism 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0165109.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165109.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="50410" pm="."><plain><italic>FGFR3-TACC3</italic> fusion transcript detection by RT-PCR. </plain></SENT>
</text></title><p><text><SENT sid="50411" pm="."><plain>(A) Schematic representation of <italic>FGFR3-TACC3</italic> fusion mRNA and PCR primers position. </plain></SENT>
<SENT sid="50412" pm="."><plain>(B) Agarose gel separation of the <italic>FGFR3-TACC3</italic> fusion specific RT-PCR amplicons. </plain></SENT>
<SENT sid="50413" pm="."><plain>(C) Sanger sequencing chromatogram of <italic>FGFR3-TACC3</italic> fusion specific RT-PCR products. </plain></SENT>
<SENT sid="50414" pm="."><plain>The arrowhead and solid bar indicate breakdown point or region of the 2 genes. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0165109.g003"/></fig></SecTag></sec><sec id="sec013"><title><text><SENT sid="50415" pm="."><plain>Mutation analysis </plain></SENT>
</text></title><p><text><SENT sid="50416" pm="."><plain>Genomic DNA was extracted using a QIAamp DNA FFPE Tissue Kit (Qiagen) according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="50417" pm="."><plain>The DNA concentration for each sample was assessed by a Qubit fluorometer (Thermo Fisher Scientific). </plain></SENT>
<SENT sid="50418" pm="."><plain>Genomic DNA with more than 1.5 ng/μL according to the Qubit fluorometer was subjected to further mutation analysis. </plain></SENT>
<SENT sid="50419" pm="."><plain>The presence of mutations in <italic>FGFR3</italic> was analyzed by targeted sequencing using Ion AmpliSeq Cancer Hotspot Panel v2 (Thermo Fisher Scientific). </plain></SENT>
<SENT sid="50420" pm="."><plain>The targeted <italic>FGFR3</italic> mutations are listed in <xref ref-type="supplementary-material" rid="pone.0165109.s007">S1 Table</xref>. </plain></SENT>
<SENT sid="50421" pm="."><plain>For data analysis, Torrent Suite 4.0.2 was used, and mutations were detected by the Variant Caller plugin 4.0–6 with somatic/high stringency configuration provided by Ion Torrent (Thermo Fisher Scientific). </plain></SENT>
</text></p></sec><sec id="sec014"><title><text><SENT sid="50422" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="50423" pm="."><plain>Differences among groups were analyzed using Fisher’s exact test. </plain></SENT>
<SENT sid="50424" pm="."><plain>P values of &lt;0.05 were considered to be statistically significant. </plain></SENT>
<SENT sid="50425" pm="."><plain>Statistical analyses were performed using Jmp11 software (SAS Institute Inc., Cary, NC, USA). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec015"><title><text><SENT sid="50426" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec016"><title><text><SENT sid="50427" pm="."><plain>Identification of <italic>FGFR3-TACC3</italic> fusion transcripts by sequencing and RNA-FISH from xenograft FFPE tissue using human bladder cancer cell lines </plain></SENT>
</text></title><p><text><SENT sid="50428" pm="."><plain>To develop methods to detect <italic>FGFR3-TACC3</italic> fusion transcripts, we first tried RT-PCR methods using mouse xenograft models of the human BC cell lines RT112 and RT4. </plain></SENT>
<SENT sid="50429" pm="."><plain>Both cell lines were reported[<xref rid="pone.0165109.ref010" ref-type="bibr">10</xref>] to harbor <italic>FGFR3-TACC3</italic> fusion genes. </plain></SENT>
<SENT sid="50430" pm="."><plain>Xenograft tissues were divided into 2 fractions; one was stored frozen, and the other was stored as FFPE tissue. </plain></SENT>
<SENT sid="50431" pm="."><plain>The amplified products of the <italic>HPRT</italic> housekeeping gene (152 bps) were identified in FFPE samples as well as in frozen tissues. </plain></SENT>
<SENT sid="50432" pm="."><plain>PCR products of <italic>FGFR3-TACC3</italic> fusion genes were found at about 2800 bps and 4500 bps in frozen tissues from xenografts of RT112 and RT4, respectively, but not in FFPE samples (<xref ref-type="fig" rid="pone.0165109.g003">Fig 3B</xref>). </plain></SENT>
<SENT sid="50433" pm="."><plain>Sequencing of PCR products confirmed that both cell lines harbored the same break-point sequence as previously reported[<xref rid="pone.0165109.ref010" ref-type="bibr">10</xref>] (<xref ref-type="fig" rid="pone.0165109.g003">Fig 3C</xref>). </plain></SENT>
<SENT sid="50434" pm="."><plain>Next, we tried RNA-FISH to detect <italic>FGFR3</italic> and <italic>TACC3</italic> signal using xenograft FFPE tissues of RT112 (fusion-positive control) and RT4 (fusion-positive control) and HSC-39 cells (fusion-negative control). </plain></SENT>
<SENT sid="50435" pm="."><plain>Fluorescent signals for <italic>FGFR3</italic> and <italic>TACC3</italic> were detected in FFPE samples of all three xenografts. </plain></SENT>
<SENT sid="50436" pm="."><plain>Overlapped/co-localized signals were abundant in xenograft FFPE sections with RT112 and RT4, but barely detected in HSC-39 cells (<xref ref-type="fig" rid="pone.0165109.g004">Fig 4</xref>). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0165109.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165109.g004</object-id><label>Fig 4</label><caption><title><text><SENT sid="50437" pm="."><plain><italic>FGFR3-TACC3</italic> fusion transcript detection by RNA-FISH. </plain></SENT>
</text></title><p><text><SENT sid="50438" pm="."><plain>RNA-FISH image of RT112 and RT4 (fusion-positive controls) and HSC-39 (negative control) xenograft FFPE tissue. </plain></SENT>
<SENT sid="50439" pm="."><plain>mRNAs of <italic>FGFR3</italic> and <italic>TACC3</italic> were detected by RNA-ISH using fluorescent probes (Alexa 647 for <italic>FGFR3</italic> and Alexa 546 for <italic>TACC3</italic>, respectively), and signals from <italic>FGFR3</italic> and <italic>TACC3</italic> were shown as red and green, respectively, in the figure. </plain></SENT>
<SENT sid="50440" pm="."><plain>The small boxed areas are enlarged in the adjacent large boxes. </plain></SENT>
<SENT sid="50441" pm="."><plain>Fusion mRNAs appeared in microscope images as yellow, which are merged signals from red and green colors. </plain></SENT>
<SENT sid="50442" pm="."><plain>Cell nuclei was stained with DAPI and shown as blue. </plain></SENT>
<SENT sid="50443" pm="."><plain>Scale bars in the figure are 10 μm. </plain></SENT>
<SENT sid="50444" pm="."><plain>For the detection of fusion signals for each sample, image data from 2 fluorescent probes were analyzed with IN Cell Analyzer 2000 and the number of overlapped/co-localized signals was counted and divided by the total number of <italic>FGFR3</italic> signals and <italic>TACC3</italic> signals and plotted in a scatter graph. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0165109.g004"/></fig></SecTag></sec><sec id="sec017"><title><text><SENT sid="50445" pm="."><plain>Detection of <italic>FGFR3-TACC3</italic> fusion genes from clinical FFPE samples by RNA-FISH </plain></SENT>
</text></title><p><text><SENT sid="50446" pm="."><plain>To examine whether RNA-FISH is applicable to human samples, we analyzed 104 BC samples independently by RNA-FISH and Sanger sequencing to detect <italic>FGFR3-TACC3</italic> fusions as a prospective cohort study. </plain></SENT>
<SENT sid="50447" pm="."><plain>Tumor samples were freshly collected, and parts of the samples were fixed in 10% formaldehyde for 12–24 hours at room temperature and then embedded in paraffin. </plain></SENT>
<SENT sid="50448" pm="."><plain>For detection of the fusion transcript by RNA-FISH, the number of overlapped/co-localized signals was divided by the number of <italic>FGFR3</italic> signals and <italic>TACC3</italic> signals, and the quotients were plotted in a scatter graph (<xref ref-type="fig" rid="pone.0165109.g005">Fig 5</xref>). </plain></SENT>
<SENT sid="50449" pm="."><plain>The original result of signal count analysis by IN Cell Analyzer 2000 are described in <xref ref-type="supplementary-material" rid="pone.0165109.s008">S2 Table</xref>. </plain></SENT>
<SENT sid="50450" pm="."><plain>Four of 104 samples and positive controls are plotted in the right upper quadrant (both ratios of co-localized dot count/FGFR3 dot count and co-localized dot count/TACC3 dot count are greater than 0.2). </plain></SENT>
<SENT sid="50451" pm="."><plain>These 4 cases were thought to be fusion positive. </plain></SENT>
<SENT sid="50452" pm="."><plain>A representative photomicrograph of RNA-FISH in the <italic>FGFR3-TACC3</italic> fusion-positive sample TKB014 is shown in <xref ref-type="fig" rid="pone.0165109.g006">Fig 6</xref>. </plain></SENT>
<SENT sid="50453" pm="."><plain>Small gray dots in <xref ref-type="fig" rid="pone.0165109.g005">Fig 5</xref> represent the cases that were thought to be negative for the fusion gene. </plain></SENT>
<SENT sid="50454" pm="."><plain>Fluorescent signals were very weak in 2 cases (KYT004 and TMC001), so these cases were suspended from fusion analysis by RNA-FISH result. </plain></SENT>
<SENT sid="50455" pm="."><plain>To assess the sensitivity and specificity of RNA-FISH, frozen tissues from all 104 BC were tested using RT-PCR methods. </plain></SENT>
<SENT sid="50456" pm="."><plain>RT-PCR products around 2800–4500 base pairs were identified in all 4 cases with positive signals for fusion genes in RNA-FISH (<xref ref-type="fig" rid="pone.0165109.g007">Fig 7A</xref>). </plain></SENT>
<SENT sid="50457" pm="."><plain>Sanger sequencing demonstrated that these 4 cases indeed had <italic>FGFR3-TACC3</italic> fusion genes with different break-point sequences (<xref ref-type="fig" rid="pone.0165109.g007">Fig 7B</xref>). </plain></SENT>
<SENT sid="50458" pm="."><plain>Two cases were NMIBC, and the remaining 2 cases were MIBC. </plain></SENT>
<SENT sid="50459" pm="."><plain>Positive rates of <italic>FGFR3-TACC3</italic> fusion were 2/60 (3%) and 2/44 (5%) in NMIBC and MIBC patients, respectively. </plain></SENT>
<SENT sid="50460" pm="."><plain>The other 98 patients were fusion negative with both PCR and RNA-FISH. </plain></SENT>
<SENT sid="50461" pm="."><plain>The 2 suspended cases of FISH analysis (KYT004 and TMC001) were determined as fusion negative by the RT-PCR result. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0165109.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165109.g005</object-id><label>Fig 5</label><caption><title><text><SENT sid="50462" pm="."><plain>Detection of <italic>FGFR3-TACC3</italic> fusion genes in FFPE clinical samples by RNA-FISH. </plain></SENT>
</text></title><p><text><SENT sid="50463" pm="."><plain>Scatter diagram of <italic>FGFR3-TACC3</italic> co-localization ratios of 10 non-overlapping fields for each sample. </plain></SENT>
<SENT sid="50464" pm="."><plain>The number of co-localized signals was divided by the number of <italic>FGFR3</italic> signals and <italic>TACC3</italic> signals, and the quotients were plotted in Y- and X-axis, respectively. </plain></SENT>
<SENT sid="50465" pm="."><plain>Four samples in the right upper quadrant were thought to be fusion positive by RNA-FISH, and were confirmed as fusion positive by RT-PCR analysis. </plain></SENT>
<SENT sid="50466" pm="."><plain>Small gray dots represent cases that were thought to be negative for the fusion gene. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0165109.g005"/></fig></SecTag><SecTag type="FIG"><fig id="pone.0165109.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165109.g006</object-id><label>Fig 6</label><caption><title><text><SENT sid="50467" pm="."><plain>Representative RNA-FISH images of fusion-positive case TKB014. </plain></SENT>
</text></title><p><text><SENT sid="50468" pm="."><plain>The small boxed areas are enlarged in the adjacent large boxes. </plain></SENT>
<SENT sid="50469" pm="."><plain>Scale bars in the figure are 10 μm. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0165109.g006"/></fig></SecTag><SecTag type="FIG"><fig id="pone.0165109.g007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165109.g007</object-id><label>Fig 7</label><caption><title><text><SENT sid="50470" pm="."><plain>Detection of <italic>FGFR3-TACC3</italic> fusion transcripts in clinical samples by RT-PCR. </plain></SENT>
</text></title><p><text><SENT sid="50471" pm="."><plain>(A) Agarose gel separation of the <italic>FGFR3-TACC3</italic> fusion-specific RT-PCR amplicons. </plain></SENT>
<SENT sid="50472" pm="."><plain>(B) Sanger sequencing chromatogram of <italic>FGFR3-TACC3</italic> fusion-specific RT-PCR products. </plain></SENT>
<SENT sid="50473" pm="."><plain>Arrowheads indicate breakdown points of the 2 genes. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0165109.g007"/></fig></SecTag></sec><sec id="sec018"><title><text><SENT sid="50474" pm="."><plain>Relationship between <italic>FGFR3</italic> mutation, <italic>FGFR3-TACC3</italic> fusion, and clinical information </plain></SENT>
</text></title><p><text><SENT sid="50475" pm="."><plain><italic>FGFR3</italic> hotspot mutations were detected in 27/60 (45%) and 8/44 (18%) of NMIBC and MIBC cases, respectively (<xref ref-type="fig" rid="pone.0165109.g008">Fig 8A</xref>). </plain></SENT>
<SENT sid="50476" pm="."><plain>No mutation was detected in <italic>FGFR3</italic> coding regions in 3 of the 4 patients with an <italic>FGFR3-TACC3</italic> fusion. </plain></SENT>
<SENT sid="50477" pm="."><plain>One case (TKB025) with an <italic>FGFR3-TACC3</italic> fusion gene also had a concomitant mutation in <italic>FGFR3</italic> (S249C). </plain></SENT>
<SENT sid="50478" pm="."><plain>In this case, the <italic>FGFR3</italic>-S249C mutation was detected from tumor FFPE tissue-derived genomic DNA by Ion AmpliSeq Cancer Hotspot Panel v2. </plain></SENT>
<SENT sid="50479" pm="."><plain>However, the corresponding codon in the full-length <italic>FGFR3-TACC3</italic> fusion transcript was not altered. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0165109.g008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165109.g008</object-id><label>Fig 8</label><caption><title><text><SENT sid="50480" pm="."><plain><italic>FGFR3</italic> mutation and <italic>FGFR3-TACC3</italic> fusion status. </plain></SENT>
</text></title><p><text><SENT sid="50481" pm="."><plain>(A) The heatmap shows the distribution of <italic>FGFR3</italic> mutations and <italic>FGFR3-TACC3</italic> fusions with respect to T stage and pathological grade. </plain></SENT>
<SENT sid="50482" pm="."><plain>(B) Subgroup analysis of NMIBC by T stage. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0165109.g008"/></fig></SecTag><p><text><SENT sid="50483" pm="."><plain>Among NMIBC cases, <italic>FGFR3</italic> mutation/fusion were more frequent (<xref ref-type="fig" rid="pone.0165109.g008">Fig 8A</xref>) in low-grade tumors (21/34; 62%) than in high-grade tumors (7/26; 27%) (<italic>P</italic> = 0.0066). </plain></SENT>
<SENT sid="50484" pm="."><plain>In a subgroup analysis of NMIBC tumors by T stage, <italic>FGFR3</italic> mutations/fusions were more frequent in Ta tumors (25/43, 58%) than in T1 tumors (3/16, 19%) (<italic>P</italic> = 0.034) (<xref ref-type="fig" rid="pone.0165109.g008">Fig 8B</xref>). </plain></SENT>
<SENT sid="50485" pm="."><plain>The presence of an <italic>FGFR3</italic> mutation/fusion was not associated with tumor size or tumor multiplicity in either NMIBC or MIBC patients. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec019"><title><text><SENT sid="50486" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="50487" pm="."><plain>Generally, fusion genes are detected by immunohistochemistry (IHC), FISH, and RT-PCR. </plain></SENT>
<SENT sid="50488" pm="."><plain>IHC assays have demonstrated a wide variation in sensitivity and specificity in FFPE tissues[<xref rid="pone.0165109.ref029" ref-type="bibr">29</xref>]. </plain></SENT>
<SENT sid="50489" pm="."><plain>Specimen processing, antigen retrieval, and immunodetection systems have significant effects on the results of IHC staining[<xref rid="pone.0165109.ref030" ref-type="bibr">30</xref>]. </plain></SENT>
<SENT sid="50490" pm="."><plain>In addition, positive IHC staining does not represent the chimeric fusion protein itself but the expression level of one of the fusion partner genes. </plain></SENT>
<SENT sid="50491" pm="."><plain>In glioblastoma, possible associations between IHC staining of FGFR3 protein and the presence of <italic>FGFR3-TACC3</italic> fusion were reported[<xref rid="pone.0165109.ref011" ref-type="bibr">11</xref>][<xref rid="pone.0165109.ref017" ref-type="bibr">17</xref>]. </plain></SENT>
<SENT sid="50492" pm="."><plain>In the present study, 75% of <italic>FGFR3-TACC3</italic> fusion-positive tumors showed a high level of FGFR3 protein staining (<xref ref-type="supplementary-material" rid="pone.0165109.s001">S1 Appendix</xref>). </plain></SENT>
<SENT sid="50493" pm="."><plain>Further studies are needed to confirm this association. </plain></SENT>
<SENT sid="50494" pm="."><plain>In addition, the FGFR3 protein expression level and <italic>FGFR3</italic> mutation status were found to be significantly associated[<xref rid="pone.0165109.ref031" ref-type="bibr">31</xref>][<xref rid="pone.0165109.ref032" ref-type="bibr">32</xref>], but 15–26% of <italic>FGFR3</italic> mutant tumors showed low levels of FGFR3 expression by IHC. </plain></SENT>
<SENT sid="50495" pm="."><plain>In the present study, 12% of <italic>FGFR3</italic> mutant tumors showed a low level of FGFR3 protein staining (<xref ref-type="supplementary-material" rid="pone.0165109.s001">S1 Appendix</xref>). </plain></SENT>
<SENT sid="50496" pm="."><plain>These cases could be missed if IHC is used as a screening tool for the detection of patients who bear an <italic>FGFR3</italic> mutation or <italic>FGFR3-TACC3</italic> fusion. </plain></SENT>
</text></p><p><text><SENT sid="50497" pm="."><plain>As mentioned in the introduction, genomic DNA-FISH is not a feasible option to detect <italic>FGFR3-TACC3</italic> fusion. </plain></SENT>
<SENT sid="50498" pm="."><plain>RNA-FISH is another option to detect fusion transcripts from FFPE tissue. </plain></SENT>
<SENT sid="50499" pm="."><plain>There are several technologies that can be used to detect mRNA transcripts, which include padlock probes/RCA, “smFISH,” and “bDNA-FISH,” as summarized in a previous article[<xref rid="pone.0165109.ref033" ref-type="bibr">33</xref>]. </plain></SENT>
<SENT sid="50500" pm="."><plain>Femino et al. were the first to describe the visualization of single RNA molecules by FISH[<xref rid="pone.0165109.ref034" ref-type="bibr">34</xref>]. </plain></SENT>
<SENT sid="50501" pm="."><plain>Raj et al. improved the original single-molecule RNA FISH (smFISH) using short oligos each labeled with a single fluorophore[<xref rid="pone.0165109.ref035" ref-type="bibr">35</xref>]. “smFISH” was applied by Semrau et al. (FuseFISH)[<xref rid="pone.0165109.ref020" ref-type="bibr">20</xref>] and Markey et al. (Fusion FISH)[<xref rid="pone.0165109.ref019" ref-type="bibr">19</xref>] to detect oncogenic fusion transcripts. </plain></SENT>
<SENT sid="50502" pm="."><plain>In “bDNA-FISH,” multiple pairs of primary probes are required to hybridize in a juxtaposed position (double Z design) in order to proceed with branched DNA hybridization for signal amplification (<xref ref-type="fig" rid="pone.0165109.g002">Fig 2</xref>). </plain></SENT>
<SENT sid="50503" pm="."><plain>This contributes increased specificity and reduced background signal. </plain></SENT>
<SENT sid="50504" pm="."><plain>This method is commercially available as a QuantiGene® VeiwRNA kit (Affymetrix) or RNAScope® kit (Advanced Cell Diagnostics). </plain></SENT>
<SENT sid="50505" pm="."><plain>Battich et al. reported that “smFISH” and “bDNA-FISH” demonstrate the same accuracy, but that bDNA-FISH yielded brighter spots with a better signal-to-noise ratio(22). </plain></SENT>
</text></p><p><text><SENT sid="50506" pm="."><plain>Here we used this bDNA-FISH-based “QuantiGene® ViewRNA ISH Tissue Assay Kit” to detect fusion mRNA. </plain></SENT>
<SENT sid="50507" pm="."><plain>This assay is suitable for not only fresh tissue, but also archival FFPE tissues. </plain></SENT>
<SENT sid="50508" pm="."><plain>Urdinguio et al. assessed 124 FFPE human colon cancer tissues that had been stored more than 5 years. </plain></SENT>
<SENT sid="50509" pm="."><plain>They confirmed that <italic>GM-CSF</italic> (<italic>granulocyte-macrophage colony-stimulating factor</italic>) mRNA was overexpressed in human colorectal cancer using this assay[<xref rid="pone.0165109.ref036" ref-type="bibr">36</xref>]. </plain></SENT>
<SENT sid="50510" pm="."><plain>Weier et al. evaluated the expression level of ETV4 and ETV5 in 83 FFPE human prostate cancer tissue samples that had been stored 8 to 19 years[<xref rid="pone.0165109.ref037" ref-type="bibr">37</xref>]. </plain></SENT>
<SENT sid="50511" pm="."><plain>In this study, we developed an RNA-FISH assay using bDNA probe to detect <italic>FGFR3-TACC3</italic> fusion and assessed its sensitivity and specificity using FFPE human samples. </plain></SENT>
<SENT sid="50512" pm="."><plain>The results of RNA-FISH using FFPE sections were identical to those obtained by RT-PCR using frozen tissues, indicating that RNA-FISH is a feasible assay for screening for <italic>FGFR3-TACC3</italic> fusion. </plain></SENT>
<SENT sid="50513" pm="."><plain>Our data suggested that an RNA-FISH for fusion genes might be feasible for screening other fusion genes when genomic DNA-FISH lacks utility. </plain></SENT>
</text></p><p><text><SENT sid="50514" pm="."><plain>RT-PCR was thought to be another option to detect <italic>FGFR3-TACC3</italic> fusion transcripts in FFPE tissue. </plain></SENT>
<SENT sid="50515" pm="."><plain>To detect all known and possibly new variants of <italic>FGFR3-TACC3</italic> fusions, the forward primer needs to recognize a sequence upstream of exon 18 of the <italic>FGFR3</italic> and the reverse primer downstream of exon 13 of the <italic>TACC3</italic>. </plain></SENT>
<SENT sid="50516" pm="."><plain>The size of the PCR amplicon using this primer pair varies by case from between 100 to more than 1,000 base pairs. </plain></SENT>
<SENT sid="50517" pm="."><plain>RNA obtained from FFPE tissues is generally highly degraded, making it difficult to detect a PCR amplicon of several hundred base pairs or more. </plain></SENT>
<SENT sid="50518" pm="."><plain>Even if we design a multiplex PCR primer to cover to all known combinations of exons on the <italic>FGFR3</italic> and <italic>TACC3</italic>, the expected length of the PCR amplicon varies by case for the following reasons. </plain></SENT>
<SENT sid="50519" pm="."><plain>First, the genomic break point could be different in each case. </plain></SENT>
<SENT sid="50520" pm="."><plain>Second, introns could be inserted between the genomic break point of the <italic>FGFR3</italic> and <italic>TACC3</italic> genes in some cases[<xref rid="pone.0165109.ref027" ref-type="bibr">27</xref>]. </plain></SENT>
<SENT sid="50521" pm="."><plain>Actually, 36 bps of intron 10 of the <italic>TACC3</italic> gene were inserted into fusion mRNA in TKB014 in our study. </plain></SENT>
<SENT sid="50522" pm="."><plain>Thus, the expected lengths of PCR amplicons of the ready-made multiplex PCR primer for each exon were unequal and predisposed to give a false negative. </plain></SENT>
<SENT sid="50523" pm="."><plain>Recently, targeted sequencing using next-generation sequencing was applied for detection of fusion genes. </plain></SENT>
<SENT sid="50524" pm="."><plain>Ross et al. applied targeted sequencing to FFPE tissues of 35 UC patients, and the <italic>FGFR3-TACC3</italic> fusion was detected in one patient[<xref rid="pone.0165109.ref038" ref-type="bibr">38</xref>]. </plain></SENT>
<SENT sid="50525" pm="."><plain>Targeted sequencing might be an option to detect fusion genes when fusion partners are already known. </plain></SENT>
</text></p><p><text><SENT sid="50526" pm="."><plain>In previous studies, the frequencies of <italic>FGFR3</italic> mutations were 60–80% of the low-grade NMIBC and 5–20% of the invasive tumors[<xref rid="pone.0165109.ref002" ref-type="bibr">2</xref>][<xref rid="pone.0165109.ref039" ref-type="bibr">39</xref>][<xref rid="pone.0165109.ref040" ref-type="bibr">40</xref>][<xref rid="pone.0165109.ref041" ref-type="bibr">41</xref>][<xref rid="pone.0165109.ref042" ref-type="bibr">42</xref>], which is consistent with the results of the present study. </plain></SENT>
<SENT sid="50527" pm="."><plain>As reported in many previous studies[<xref rid="pone.0165109.ref043" ref-type="bibr">43</xref>][<xref rid="pone.0165109.ref044" ref-type="bibr">44</xref>], the proportion of cases having an <italic>FGFR3</italic> mutation decreased with increasing stage and grade. </plain></SENT>
<SENT sid="50528" pm="."><plain>In this study, <italic>FGFR3-TACC3</italic> fusion genes were present in 2/60 (3%) of NMIBC and 2/44 (5%) of MIBC cases. </plain></SENT>
<SENT sid="50529" pm="."><plain>In previous studies, the fusion was detected in 6% (1/17) of NMIBC cases[<xref rid="pone.0165109.ref045" ref-type="bibr">45</xref>] and 2–4% (3/129[<xref rid="pone.0165109.ref046" ref-type="bibr">46</xref>], 2/46[<xref rid="pone.0165109.ref010" ref-type="bibr">10</xref>], 1/25[<xref rid="pone.0165109.ref045" ref-type="bibr">45</xref>], and 1/35[<xref rid="pone.0165109.ref038" ref-type="bibr">38</xref>]) of MIBC cases. </plain></SENT>
<SENT sid="50530" pm="."><plain>These results are consistent with the present study. </plain></SENT>
<SENT sid="50531" pm="."><plain>Both <italic>FGFR3-TACC3</italic> fusion and <italic>FGFR3</italic>-S249C mutation were positive in case TKB025. </plain></SENT>
<SENT sid="50532" pm="."><plain>The full-length <italic>FGFR3-TACC3</italic> fusion transcript in this case did not involve a <italic>FGFR3</italic>-S249C mutation. </plain></SENT>
<SENT sid="50533" pm="."><plain>This result may indicate the presence of tumor heterogeneity of a wildtype codon 249, fusion-positive clone and codon 249 mutant, fusion negative clone. </plain></SENT>
<SENT sid="50534" pm="."><plain>In another study, 2 different <italic>FGFR3</italic> mutations were detected in a single case[<xref rid="pone.0165109.ref047" ref-type="bibr">47</xref>]. </plain></SENT>
<SENT sid="50535" pm="."><plain>The association between the presence of an <italic>FGFR3-TACC3</italic> fusion gene and the prognosis of UC is still unclear. </plain></SENT>
<SENT sid="50536" pm="."><plain>We plan to follow the subjects of this prospective study with detailed clinical information for three years. </plain></SENT>
<SENT sid="50537" pm="."><plain>In the future, we hope we can provide additional evidence. </plain></SENT>
</text></p><p><text><SENT sid="50538" pm="."><plain>The selection of an optimal drug is determined by the genetic profile of some cancers, including lung cancer, breast cancer, and leukemia. </plain></SENT>
<SENT sid="50539" pm="."><plain>Patient selection by molecular foundation is not yet indicated for metastatic UC. </plain></SENT>
<SENT sid="50540" pm="."><plain>Significant clinical responses were reported in <italic>FGFR3-TACC3</italic> fusion-positive cervical cancer patients and glioma patients treated with an FGFR inhibitor[<xref rid="pone.0165109.ref011" ref-type="bibr">11</xref>][<xref rid="pone.0165109.ref014" ref-type="bibr">14</xref>]. </plain></SENT>
<SENT sid="50541" pm="."><plain>However, the <italic>FGFR3</italic> mutation is not very frequent among metastatic UC patients, comprising about 6–18% (2/35[<xref rid="pone.0165109.ref038" ref-type="bibr">38</xref>], 2/11[<xref rid="pone.0165109.ref047" ref-type="bibr">47</xref>], and 3/33[<xref rid="pone.0165109.ref048" ref-type="bibr">48</xref>]). </plain></SENT>
<SENT sid="50542" pm="."><plain>The screening of not only the <italic>FGFR3</italic> mutation, but also the <italic>FGFR3-TACC3</italic> fusion gene makes it possible to find additional responders to FGFR inhibitors. </plain></SENT>
</text></p><p><text><SENT sid="50543" pm="."><plain>A limitation of this method is that it cannot detect fusions other than <italic>FGFR3-TACC3</italic>. <italic>BAIAP2L1</italic>(<italic>BAI1-associated protein 2-like 1</italic>) was reported as another fusion partner of <italic>FGFR3</italic> in lung cancer patients[<xref rid="pone.0165109.ref049" ref-type="bibr">49</xref>] and BC cell lines[<xref rid="pone.0165109.ref010" ref-type="bibr">10</xref>]. </plain></SENT>
<SENT sid="50544" pm="."><plain>The fusion gene leads to a constitutive activation of the <italic>FGFR3</italic> tyrosine kinase domain. </plain></SENT>
<SENT sid="50545" pm="."><plain>An <italic>FGFR3-BAIAP2L1</italic> fusion-positive cell line showed sensitivity to an FGFR inhibitor in vitro[<xref rid="pone.0165109.ref050" ref-type="bibr">50</xref>]. </plain></SENT>
<SENT sid="50546" pm="."><plain>In this study, the <italic>FGFR3-BAIAP2L1</italic> fusion gene was not examined. </plain></SENT>
<SENT sid="50547" pm="."><plain>The association between the <italic>FGFR3-BAIAP2L1</italic> fusion and clinical stages of UC is still unclear. </plain></SENT>
<SENT sid="50548" pm="."><plain>The importance of the detection for this fusion will be determined by further investigation of its frequency in BC. </plain></SENT>
<SENT sid="50549" pm="."><plain>The <italic>BAIAP2L1</italic> gene is located on chromosome 7 at position 7q22.1, which is a different chromosome from the location of the <italic>FGFR3</italic> gene. </plain></SENT>
<SENT sid="50550" pm="."><plain>The <italic>FGFR3-BAIAP2L1</italic> fusion has been detected by DNA-FISH, which is easily applied to clinical cases[<xref rid="pone.0165109.ref010" ref-type="bibr">10</xref>][<xref rid="pone.0165109.ref050" ref-type="bibr">50</xref>]. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusions" id="sec020"><title><text><SENT sid="50551" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="50552" pm="."><plain>In this study, we applied an RNA-FISH assay to detect <italic>FGFR3-TACC3</italic> fusion transcripts in 104 FFPE BC tissues. </plain></SENT>
<SENT sid="50553" pm="."><plain>We demonstrated that RNA-FISH is a feasible assay to screen for the <italic>FGFR3-TACC3</italic> fusion. </plain></SENT>
<SENT sid="50554" pm="."><plain>We also analyzed the association of <italic>FGFR3</italic> mutation/fusion status and clinical information in a prospective multicenter cohort of 104 patients with a clinical diagnosis of BC. </plain></SENT>
<SENT sid="50555" pm="."><plain>The efficiency of the bDNA-FISH assay needs to be confirmed in a larger series of cases and possibly compared with the smFISH methodology that has also been reported to be an accurate approach for the detection of fusion transcripts, before it could be considered the technique of choice to identify additional responders to FGFR inhibitors. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec021"><title><text><SENT sid="50556" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0165109.s001"><label>S1 Appendix</label><caption><title><text><SENT sid="50557" pm="."><plain>FGFR3 Protein Expression Analysis in Tissue Samples Using Tissue Microarrays </plain></SENT>
</text></title><p><text><SENT sid="50558" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0165109.s001.docx"><caption><p><text><SENT sid="50559" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0165109.s002"><label>S1 Fig</label><caption><title><text><SENT sid="50560" pm="."><plain>A schematic representation of how co-localized signals were detected by IN Cell Investigator Developer Toolbox 1.9.2. </plain></SENT>
</text></title><p><text><SENT sid="50561" pm="."><plain>(TIF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0165109.s002.tif"><caption><p><text><SENT sid="50562" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0165109.s003"><label>S2 Fig</label><caption><title><text><SENT sid="50563" pm="."><plain>Low-power view of one of the tissue microarrays with FGFR3 immunostaining. </plain></SENT>
</text></title><p><text><SENT sid="50564" pm="."><plain>Scale bar = 5 mm. </plain></SENT>
</text></p><p><text><SENT sid="50565" pm="."><plain>(TIF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0165109.s003.tif"><caption><p><text><SENT sid="50566" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0165109.s004"><label>S3 Fig</label><caption><title><text><SENT sid="50567" pm="."><plain>Patterns of FGFR3 staining intensity. </plain></SENT>
</text></title><p><text><SENT sid="50568" pm="."><plain>(A) Staining pattern 0; (B) staining pattern 1; (C) staining pattern 2; (D) staining pattern 3. </plain></SENT>
<SENT sid="50569" pm="."><plain>Scale bars = 100 μm. </plain></SENT>
</text></p><p><text><SENT sid="50570" pm="."><plain>(TIF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0165109.s004.tif"><caption><p><text><SENT sid="50571" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0165109.s005"><label>S4 Fig</label><caption><title><text><SENT sid="50572" pm="."><plain>Comparison of FGFR3 staining intensity with FGFR3 mutation and FGFR3-TACC3 fusion status. </plain></SENT>
</text></title><p><text><SENT sid="50573" pm="."><plain>Dark blue bars = High, Light blue bars = Low. </plain></SENT>
</text></p><p><text><SENT sid="50574" pm="."><plain>(TIF) </plain></SENT>
</text></p></caption><media xlink:href="pone.0165109.s005.tif"><caption><p><text><SENT sid="50575" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0165109.s006"><label>S1 Protocol</label><caption><title><text><SENT sid="50576" pm="."><plain>A step-by-step protocol for RNA FISH using a ViewRNA kit. </plain></SENT>
</text></title><p><text><SENT sid="50577" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0165109.s006.docx"><caption><p><text><SENT sid="50578" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0165109.s007"><label>S1 Table</label><caption><title><text><SENT sid="50579" pm="."><plain>The list of targeted FGFR3 mutations for Ion AmpliSeq Cancer Hotspot Panel v2. </plain></SENT>
</text></title><p><text><SENT sid="50580" pm="."><plain>The original excel file is available at: <ext-link ext-link-type="uri" xlink:href="http://tools.invitrogen.com/downloads/cms_106003.csv">http://tools.invitrogen.com/downloads/cms_106003.csv</ext-link> </plain></SENT>
</text></p><p><text><SENT sid="50581" pm="."><plain>(XLSX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0165109.s007.xlsx"><caption><p><text><SENT sid="50582" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0165109.s008"><label>S2 Table</label><caption><title><text><SENT sid="50583" pm="."><plain>The result of RNA-FISH image analysis by IN Cell Analyzer 2000. </plain></SENT>
</text></title><p><text><SENT sid="50584" pm="."><plain>(XLSX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0165109.s008.xlsx"><caption><p><text><SENT sid="50585" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0165109.s009"><label>S3 Table</label><caption><title><text><SENT sid="50586" pm="."><plain>FGFR3 staining intensity and <italic>FGFR3</italic> mutation/<italic>FGFR3-TACC3</italic> fusion status. </plain></SENT>
</text></title><p><text><SENT sid="50587" pm="."><plain>(XLSX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0165109.s009.xlsx"><caption><p><text><SENT sid="50588" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="50589" pm="."><plain>We are grateful to Dr. Hiroyuki Tsunemori, Dr Taeko Matsuoka and Dr. Naoto Keino for their valuable contributions to the collection of materials and clinical information. </plain></SENT>
<SENT sid="50590" pm="."><plain>We thank Noriko Kunita, Taeko Asano and Jun Itadani for their excellent technical assistance. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0165109.ref001"><text><SENT sid="50591" pm="."><plain><label>1</label><mixed-citation publication-type="journal"><name><surname>van Rhijn</surname><given-names>BW</given-names></name>, <name><surname>van Tilborg</surname><given-names>AA</given-names></name>, <name><surname>Lurkin</surname><given-names>I</given-names></name>, <name><surname>Bonaventure</surname><given-names>J</given-names></name>, <name><surname>de Vries</surname><given-names>A</given-names></name>, <name><surname>Thiery</surname><given-names>JP</given-names></name>, <etal>et al</etal> <article-title>Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders</article-title>. <source>Eur J Hum Genet</source> <year>2002</year>;<volume>10</volume>:<fpage>819</fpage>–<lpage>824</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejhg.5200883</pub-id> <?supplied-pmid 12461689?><pub-id pub-id-type="pmid">12461689</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref002"><text><SENT sid="50592" pm="."><plain><label>2</label><mixed-citation publication-type="journal"><name><surname>Knowles</surname><given-names>MA</given-names></name>, <name><surname>Hurst</surname><given-names>CD</given-names></name>. <article-title>Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity</article-title>. <source>Nat Rev Cancer</source> <year>2015</year>; <volume>15</volume>:<fpage>25</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1038/nrc3817</pub-id> <?supplied-pmid 25533674?><pub-id pub-id-type="pmid">25533674</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref003"><text><SENT sid="50593" pm="."><plain><label>3</label><mixed-citation publication-type="journal"><name><surname>Tomlinson</surname><given-names>DC</given-names></name>, <name><surname>Baldo</surname><given-names>O</given-names></name>, <name><surname>Harnden</surname><given-names>P</given-names></name>, <name><surname>Knowles</surname><given-names>MA</given-names></name>. <article-title>FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer</article-title>. <source>J Pathol</source> <year>2007</year>;<volume>213</volume>:<fpage>91</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1002/path.2207</pub-id> <?supplied-pmid 17668422?><pub-id pub-id-type="pmid">17668422</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref004"><text><SENT sid="50594" pm="."><plain><label>4</label><mixed-citation publication-type="journal"><name><surname>Adar</surname><given-names>R</given-names></name>, <name><surname>Monsonego-Ornan</surname><given-names>E</given-names></name>, <name><surname>David</surname><given-names>P</given-names></name>, <name><surname>Yayon</surname><given-names>A</given-names></name>. <article-title>Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization</article-title>. <source>J Bone Miner Res</source> <year>2002</year>;<volume>17</volume>:<fpage>860</fpage>–<lpage>868</lpage>. <pub-id pub-id-type="doi">10.1359/jbmr.2002.17.5.860</pub-id> <?supplied-pmid 12009017?><pub-id pub-id-type="pmid">12009017</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref005"><text><SENT sid="50595" pm="."><plain><label>5</label><mixed-citation publication-type="journal"><name><surname>d'Avis</surname><given-names>PY</given-names></name>, <name><surname>Robertson</surname><given-names>SC</given-names></name>, <name><surname>Meyer</surname><given-names>AN</given-names></name>, <name><surname>Bardwell</surname><given-names>WM</given-names></name>, <name><surname>Webster</surname><given-names>MK</given-names></name>, <name><surname>Donoghue</surname><given-names>DJ</given-names></name>. <article-title>Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I</article-title>. <source>Cell Growth Differ</source> <year>1998</year>;<volume>9</volume>:<fpage>71</fpage>–<lpage>78</lpage>. <?supplied-pmid 9438390?><pub-id pub-id-type="pmid">9438390</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref006"><text><SENT sid="50596" pm="."><plain><label>6</label><mixed-citation publication-type="journal"><name><surname>Webster</surname><given-names>MK</given-names></name>, <name><surname>D'Avis</surname><given-names>PY</given-names></name>, <name><surname>Robertson</surname><given-names>SC</given-names></name>, <name><surname>Donoghue</surname><given-names>DJ</given-names></name>. <article-title>Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II</article-title>. <source>Mol Cell Biol</source> <year>1996</year>;<volume>16</volume>:<fpage>4081</fpage>–<lpage>4087</lpage>. <?supplied-pmid 8754806?><pub-id pub-id-type="pmid">8754806</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref007"><text><SENT sid="50597" pm="."><plain><label>7</label><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>D</given-names></name>, <name><surname>Chan</surname><given-names>JM</given-names></name>, <name><surname>Zoppoli</surname><given-names>P</given-names></name>, <name><surname>Niola</surname><given-names>F</given-names></name>, <name><surname>Sullivan</surname><given-names>R</given-names></name>, <name><surname>Iavarone</surname><given-names>A</given-names></name>, <etal>et al</etal> <article-title>Transforming fusions of FGFR and TACC genes in human glioblastoma</article-title>. <source>Science</source> <year>2012</year>; <volume>337</volume>:<fpage>1231</fpage>–<lpage>1235</lpage>. <pub-id pub-id-type="doi">10.1126/science.1220834</pub-id> <?supplied-pmid 22837387?><pub-id pub-id-type="pmid">22837387</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref008"><text><SENT sid="50598" pm="."><plain><label>8</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>YM</given-names></name>, <name><surname>Su</surname><given-names>F</given-names></name>, <name><surname>Kalyana-Sundaram</surname><given-names>S</given-names></name>, <name><surname>Khazanov</surname><given-names>N</given-names></name>, <name><surname>Ateeq</surname><given-names>B</given-names></name>, <name><surname>Chinnaiyan</surname><given-names>AM</given-names></name>, <etal>et al</etal> <article-title>Identification of targetable FGFR gene fusions in diverse cancers</article-title>. <source>Cancer Discov</source> <year>2013</year>;<volume>3</volume>:<fpage>636</fpage>–<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0050</pub-id> <?supplied-pmid 23558953?><pub-id pub-id-type="pmid">23558953</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref009"><text><SENT sid="50599" pm="."><plain><label>9</label><mixed-citation publication-type="journal"><name><surname>Majewski</surname><given-names>IJ</given-names></name>, <name><surname>Mittempergher</surname><given-names>L</given-names></name>, <name><surname>Davidson</surname><given-names>NM</given-names></name>, <name><surname>Bosma</surname><given-names>A</given-names></name>, <name><surname>Willems</surname><given-names>SM</given-names></name>, <name><surname>Bernards</surname><given-names>R</given-names></name>, <etal>et al</etal> <article-title>Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing</article-title>. <source>J Pathol</source>. <year>2013</year>;<volume>230</volume>:<fpage>270</fpage>–<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1002/path.4209</pub-id> <?supplied-pmid 23661334?><pub-id pub-id-type="pmid">23661334</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref010"><text><SENT sid="50600" pm="."><plain><label>10</label><mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>SV</given-names></name>, <name><surname>Hurst</surname><given-names>CD</given-names></name>, <name><surname>Knowles</surname><given-names>MA</given-names></name>. <article-title>Oncogenic FGFR3 gene fusions in bladder cancer</article-title>. <source>Hum Mol Genet</source> <year>2013</year>;<volume>22</volume>:<fpage>795</fpage>–<lpage>803</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/dds486</pub-id> <?supplied-pmid 23175443?><pub-id pub-id-type="pmid">23175443</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref011"><text><SENT sid="50601" pm="."><plain><label>11</label><mixed-citation publication-type="journal"><name><surname>Di Stefano</surname><given-names>AL</given-names></name>, <name><surname>Fucci</surname><given-names>A</given-names></name>, <name><surname>Frattini</surname><given-names>V</given-names></name>, <name><surname>Labussiere</surname><given-names>M</given-names></name>, <name><surname>Mokhtari</surname><given-names>K</given-names></name>, <name><surname>Iavarone</surname><given-names>A</given-names></name>, <etal>et al</etal> <article-title>Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma</article-title>. <source>Clin Cancer Res</source> <year>2015</year>;<volume>21</volume>:<fpage>3307</fpage>–<lpage>3317</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2199</pub-id> <?supplied-pmid 25609060?><pub-id pub-id-type="pmid">25609060</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref012"><text><SENT sid="50602" pm="."><plain><label>12</label><mixed-citation publication-type="journal"><name><surname>Tomlinson</surname><given-names>DC</given-names></name>, <name><surname>Hurst</surname><given-names>CD</given-names></name>, <name><surname>Knowles</surname><given-names>MA</given-names></name>. <article-title>Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer</article-title>. <source>Oncogene</source> <year>2007</year>;<volume>26</volume>:<fpage>5889</fpage>–<lpage>5899</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1210399</pub-id> <?supplied-pmid 17384684?><pub-id pub-id-type="pmid">17384684</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref013"><text><SENT sid="50603" pm="."><plain><label>13</label><mixed-citation publication-type="journal"><name><surname>Bernard-Pierrot</surname><given-names>I</given-names></name>, <name><surname>Brams</surname><given-names>A</given-names></name>, <name><surname>Dunois-Lardé</surname><given-names>C</given-names></name>, <name><surname>Caillault</surname><given-names>A</given-names></name>, <name><surname>Diez de Medina</surname><given-names>SG</given-names></name>, <name><surname>Radvanyi</surname><given-names>F</given-names></name>, <etal>et al</etal> <article-title>Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b</article-title>. <source>Carcinogenesis</source> <year>2006</year>;<volume>27</volume>:<fpage>740</fpage>–<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgi290</pub-id> <?supplied-pmid 16338952?><pub-id pub-id-type="pmid">16338952</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref014"><text><SENT sid="50604" pm="."><plain><label>14</label><mixed-citation publication-type="journal"><name><surname>Carneiro</surname><given-names>BA</given-names></name>, <name><surname>Elvin</surname><given-names>JA</given-names></name>, <name><surname>Kamath</surname><given-names>SD</given-names></name>, <name><surname>Ali</surname><given-names>SM</given-names></name>, <name><surname>Paintal</surname><given-names>AS</given-names></name>, <name><surname>Johnson</surname><given-names>ML</given-names></name>, <etal>et al</etal> <article-title>FGFR3-TACC3: A novel gene fusion in cervical cancer</article-title>. <source>Gynecol Oncol Rep</source> <year>2015</year>;<volume>13</volume>:<fpage>53</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.gore.2015.06.005</pub-id> <?supplied-pmid 26425723?><pub-id pub-id-type="pmid">26425723</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref015"><text><SENT sid="50605" pm="."><plain><label>15</label><mixed-citation publication-type="journal"><name><surname>Tkachuk</surname><given-names>DC</given-names></name>, <name><surname>Westbrook</surname><given-names>CA</given-names></name>, <name><surname>Andreeff</surname><given-names>M</given-names></name>, <name><surname>Donlon</surname><given-names>TA</given-names></name>, <name><surname>Cleary</surname><given-names>ML</given-names></name>, <name><surname>Pinkel</surname><given-names>D</given-names></name>, <etal>et al</etal> <article-title>Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization</article-title>. <source>Science</source> <year>1990</year>;<volume>250</volume>:<fpage>559</fpage>–<lpage>562</lpage>. <?supplied-pmid 2237408?><pub-id pub-id-type="pmid">2237408</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref016"><text><SENT sid="50606" pm="."><plain><label>16</label><mixed-citation publication-type="journal"><name><surname>Perner</surname><given-names>S</given-names></name>, <name><surname>Wagner</surname><given-names>PL</given-names></name>, <name><surname>Demichelis</surname><given-names>F</given-names></name>, <name><surname>Mehra</surname><given-names>R</given-names></name>, <name><surname>Lafargue</surname><given-names>CJ</given-names></name>, <name><surname>Rubin</surname><given-names>MA</given-names></name>, <etal>et al</etal> <article-title>EML4-ALK fusion lung cancer: a rare acquired event</article-title>. <source>Neoplasia</source> <year>2008</year>;<volume>10</volume>:<fpage>298</fpage>–<lpage>302</lpage>. <?supplied-pmid 18320074?><pub-id pub-id-type="pmid">18320074</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref017"><text><SENT sid="50607" pm="."><plain><label>17</label><mixed-citation publication-type="journal"><name><surname>Parker</surname><given-names>BC</given-names></name>, <name><surname>Annala</surname><given-names>MJ</given-names></name>, <name><surname>Cogdell</surname><given-names>DE</given-names></name>, <name><surname>Granberg</surname><given-names>KJ</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <etal>et al</etal> <article-title>The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma</article-title>. <source>J Clin Invest</source> <year>2013</year>;<volume>123</volume>:<fpage>855</fpage>–<lpage>865</lpage>. <pub-id pub-id-type="doi">10.1172/JCI67144</pub-id> <?supplied-pmid 23298836?><pub-id pub-id-type="pmid">23298836</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref018"><text><SENT sid="50608" pm="."><plain><label>18</label><mixed-citation publication-type="journal"><name><surname>Kiflemariam</surname><given-names>S</given-names></name>, <name><surname>Mignardi</surname><given-names>M</given-names></name>, <name><surname>Ali</surname><given-names>MA</given-names></name>, <name><surname>Bergh</surname><given-names>A</given-names></name>, <name><surname>Nilsson</surname><given-names>M</given-names></name>, <name><surname>Sjöblom</surname><given-names>T</given-names></name>. <article-title>In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers</article-title>. <source>J Pathol</source> <year>2014</year>;<volume>234</volume>:<fpage>253</fpage>–<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1002/path.4392</pub-id> <?supplied-pmid 24931216?><pub-id pub-id-type="pmid">24931216</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref019"><text><SENT sid="50609" pm="."><plain><label>19</label><mixed-citation publication-type="journal"><name><surname>Markey</surname><given-names>FB</given-names></name>, <name><surname>Ruezinsky</surname><given-names>W</given-names></name>, <name><surname>Tyagi</surname><given-names>S</given-names></name>, <name><surname>Batish</surname><given-names>M</given-names></name>. <article-title>Fusion FISH imaging: single-molecule detection of gene fusion transcripts in situ</article-title>. <source>PLoS One</source> <year>2014</year>;<volume>9</volume>:<fpage>e93488</fpage> <pub-id pub-id-type="doi">10.1371/journal.pone.0093488</pub-id> <?supplied-pmid 24675777?><pub-id pub-id-type="pmid">24675777</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref020"><text><SENT sid="50610" pm="."><plain><label>20</label><mixed-citation publication-type="journal"><name><surname>Semrau</surname><given-names>S</given-names></name>, <name><surname>Crosetto</surname><given-names>N</given-names></name>, <name><surname>Bienko</surname><given-names>M</given-names></name>, <name><surname>Boni</surname><given-names>M</given-names></name>, <name><surname>Bernasconi</surname><given-names>P</given-names></name>, <name><surname>van Oudenaarden</surname><given-names>A</given-names></name>, <etal>et al</etal> <article-title>FuseFISH: robust detection of transcribed gene fusions in single cells</article-title>. <source>Cell Rep</source> <year>2014</year>;<volume>6</volume>:<fpage>18</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2013.12.002</pub-id> <?supplied-pmid 24373969?><pub-id pub-id-type="pmid">24373969</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref021"><text><SENT sid="50611" pm="."><plain><label>21</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>B</given-names></name>, <name><surname>Maqsodi</surname><given-names>B</given-names></name>, <name><surname>Yang</surname><given-names>W</given-names></name>, <name><surname>McMaster</surname><given-names>GK</given-names></name>, <name><surname>Perner</surname><given-names>S</given-names></name>, <name><surname>Sanda</surname><given-names>MG</given-names></name>, <etal>et al</etal> <article-title>Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA</article-title>. <source>Urology</source> <year>2009</year>;<volume>74</volume>:<fpage>1156</fpage>–<lpage>1161</lpage>. <pub-id pub-id-type="doi">10.1016/j.urology.2009.01.087</pub-id> <?supplied-pmid 19647299?><pub-id pub-id-type="pmid">19647299</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref022"><text><SENT sid="50612" pm="."><plain><label>22</label><mixed-citation publication-type="journal"><name><surname>Battich</surname><given-names>N</given-names></name>, <name><surname>Stoeger</surname><given-names>T</given-names></name>, <name><surname>Pelkmans</surname><given-names>L</given-names></name>. <article-title>Image-based transcriptomics in thousands of single human cells at single-molecule resolution</article-title>. <source>Nat Methods</source> <year>2013</year>;<volume>10</volume>:<fpage>1127</fpage>–<lpage>1133</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2657</pub-id> <?supplied-pmid 24097269?><pub-id pub-id-type="pmid">24097269</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref023"><text><SENT sid="50613" pm="."><plain><label>23</label><mixed-citation publication-type="journal"><name><surname>Marshall</surname><given-names>CJ</given-names></name>, <name><surname>Franks</surname><given-names>LM</given-names></name>, <name><surname>Carbonell</surname><given-names>AW</given-names></name>. <article-title>Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas</article-title>. <source>J Natl Cancer Inst</source> <year>1977</year>;<volume>58</volume>:<fpage>1743</fpage>–<lpage>1751</lpage>. <?supplied-pmid 864752?><pub-id pub-id-type="pmid">864752</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref024"><text><SENT sid="50614" pm="."><plain><label>24</label><mixed-citation publication-type="journal"><name><surname>Rigby</surname><given-names>CC</given-names></name>, <name><surname>Franks</surname><given-names>LM</given-names></name>. <article-title>A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure</article-title>. <source>Br J Cancer</source> <year>1970</year>;<volume>24</volume>:<fpage>746</fpage>–<lpage>754</lpage>. <?supplied-pmid 5503601?><pub-id pub-id-type="pmid">5503601</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref025"><text><SENT sid="50615" pm="."><plain><label>25</label><mixed-citation publication-type="journal"><name><surname>Bubeník</surname><given-names>J</given-names></name>, <name><surname>Baresová</surname><given-names>M</given-names></name>, <name><surname>Viklický</surname><given-names>V</given-names></name>, <name><surname>Jakoubková</surname><given-names>J</given-names></name>, <name><surname>Sainerová</surname><given-names>H</given-names></name>, <name><surname>Donner</surname><given-names>J</given-names></name>, <etal>et al</etal> <article-title>Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen</article-title>. <source>Int J Cancer</source> <year>1973</year>;<volume>11</volume>:<fpage>765</fpage>–<lpage>773</lpage>. <?supplied-pmid 4133950?><pub-id pub-id-type="pmid">4133950</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref026"><text><SENT sid="50616" pm="."><plain><label>26</label><mixed-citation publication-type="journal"><name><surname>Yanagihara</surname><given-names>K</given-names></name>, <name><surname>Seyama</surname><given-names>T</given-names></name>, <name><surname>Tsumuraya</surname><given-names>M</given-names></name>, <name><surname>Kamada</surname><given-names>N</given-names></name>, <name><surname>Yokoro</surname><given-names>K</given-names></name>. <article-title>Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene</article-title>. <source>Cancer Res</source> <year>1991</year>;<volume>51</volume>:<fpage>381</fpage>–<lpage>386</lpage>. <?supplied-pmid 1846312?><pub-id pub-id-type="pmid">1846312</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref027"><text><SENT sid="50617" pm="."><plain><label>27</label><mixed-citation publication-type="other">COSMIC. </plain></SENT>
<SENT sid="50618" pm="."><plain>Available at: <ext-link ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FGFR3">http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FGFR3</ext-link></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref028"><text><SENT sid="50619" pm="."><plain><label>28</label><mixed-citation publication-type="other">Blast the human Genome. </plain></SENT>
<SENT sid="50620" pm="."><plain>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/genome/seq/hsBlast.html">http://www.ncbi.nlm.nih.gov/genome/seq/hsBlast.html</ext-link></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref029"><text><SENT sid="50621" pm="."><plain><label>29</label><mixed-citation publication-type="journal"><name><surname>Elliott</surname><given-names>K</given-names></name>, <name><surname>McQuaid</surname><given-names>S</given-names></name>, <name><surname>Salto-Tellez</surname><given-names>M</given-names></name>, <name><surname>Maxwell</surname><given-names>P</given-names></name>. <article-title>Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics</article-title>. <source>J Clin Pathol</source> <year>2015</year>;<volume>68</volume>:<fpage>766</fpage>–<lpage>770</lpage>. <pub-id pub-id-type="doi">10.1136/jclinpath-2015-203178</pub-id> <?supplied-pmid 26280782?><pub-id pub-id-type="pmid">26280782</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref030"><text><SENT sid="50622" pm="."><plain><label>30</label><mixed-citation publication-type="book"><name><surname>Hayat</surname><given-names>M A</given-names></name>. <source>Handbook of Immunohistochemistry and in situ Hybridization of Human Carcinomas</source>, volume <volume>1</volume>, p<fpage>8</fpage>, <publisher-name>Academic Press</publisher-name> <year>2006</year>.</mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref031"><text><SENT sid="50623" pm="."><plain><label>31</label><mixed-citation publication-type="journal"><name><surname>Poyet</surname><given-names>C</given-names></name>, <name><surname>Hermanns</surname><given-names>T</given-names></name>, <name><surname>Zhong</surname><given-names>Q</given-names></name>, <name><surname>Drescher</surname><given-names>E</given-names></name>, <name><surname>Eberli</surname><given-names>D</given-names></name>, <name><surname>Wild</surname><given-names>PJ</given-names></name>, <etal>et al</etal> <article-title>Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer</article-title>. <source>Oncol Lett</source> <year>2015</year>;<volume>10</volume>:<fpage>2753</fpage>–<lpage>2760</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2015.3691</pub-id> <?supplied-pmid 26722237?><pub-id pub-id-type="pmid">26722237</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref032"><text><SENT sid="50624" pm="."><plain><label>32</label><mixed-citation publication-type="journal"><name><surname>Tomlinson</surname><given-names>DC</given-names></name>, <name><surname>Baldo</surname><given-names>O</given-names></name>, <name><surname>Harnden</surname><given-names>P</given-names></name>, <name><surname>Knowles</surname><given-names>MA</given-names></name>. <article-title>FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer</article-title>. <source>J Pathol</source> <year>2007</year>;<volume>213</volume>:<fpage>91</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1002/path.2207</pub-id> <?supplied-pmid 17668422?><pub-id pub-id-type="pmid">17668422</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref033"><text><SENT sid="50625" pm="."><plain><label>33</label><mixed-citation publication-type="journal"><name><surname>Kwon</surname><given-names>S</given-names></name>, <article-title>Single-molecule fluorescence in situ hybridization: quantitative imaging of single RNA molecules</article-title>. <source>BMB Rep</source> <year>2013</year>;<volume>46</volume>:<fpage>65</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.5483/BMBRep.2013.46.2.016</pub-id> <?supplied-pmid 23433107?><pub-id pub-id-type="pmid">23433107</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref034"><text><SENT sid="50626" pm="."><plain><label>34</label><mixed-citation publication-type="journal"><name><surname>Femino</surname><given-names>AM</given-names></name>, <name><surname>Fay</surname><given-names>FS</given-names></name>, <name><surname>Fogarty</surname><given-names>K</given-names></name>, <name><surname>Singer</surname><given-names>RH</given-names></name>. <article-title>Visualization of single RNA transcripts in situ</article-title>. <source>Science</source><year>1998</year>;<volume>280</volume>:<fpage>585</fpage>–<lpage>590</lpage>. <?supplied-pmid 9554849?><pub-id pub-id-type="pmid">9554849</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref035"><text><SENT sid="50627" pm="."><plain><label>35</label><mixed-citation publication-type="journal"><name><surname>Raj</surname><given-names>A</given-names></name>, <name><surname>van den Bogaard</surname><given-names>P</given-names></name>, <name><surname>Rifkin</surname><given-names>SA</given-names></name>, <name><surname>van Oudenaarden</surname><given-names>A</given-names></name>, <name><surname>Tyagi</surname><given-names>S</given-names></name>. <article-title>Imaging individual mRNA molecules using multiple singly labeled probes</article-title>. <source>Nat Methods</source> <year>2008</year>;<volume>5</volume>:<fpage>877</fpage>–<lpage>879</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1253</pub-id> <?supplied-pmid 18806792?><pub-id pub-id-type="pmid">18806792</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref036"><text><SENT sid="50628" pm="."><plain><label>36</label><mixed-citation publication-type="journal"><name><surname>Urdinguio</surname><given-names>RG</given-names></name>, <name><surname>Fernandez</surname><given-names>AF</given-names></name>, <name><surname>Moncada-Pazos</surname><given-names>A</given-names></name>, <name><surname>Huidobro</surname><given-names>C</given-names></name>, <name><surname>Rodriguez</surname><given-names>RM</given-names></name>, <name><surname>Fraga</surname><given-names>MF</given-names></name>, <etal>et al</etal> <article-title>Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors</article-title>. <source>Cancer Res</source> <year>2013</year>;<volume>73</volume>:<fpage>395</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0806</pub-id> <?supplied-pmid 23108143?><pub-id pub-id-type="pmid">23108143</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref037"><text><SENT sid="50629" pm="."><plain><label>37</label><mixed-citation publication-type="journal"><name><surname>Weier</surname><given-names>C</given-names></name>, <name><surname>Haffner</surname><given-names>MC</given-names></name>, <name><surname>Mosbruger</surname><given-names>T</given-names></name>, <name><surname>Esopi</surname><given-names>DM</given-names></name>, <name><surname>Hicks</surname><given-names>J</given-names></name>, <name><surname>Yegnasubramanian</surname><given-names>S</given-names></name>, <etal>et al</etal> <article-title>Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer</article-title>. <source>J Pathol</source> <year>2013</year>;<volume>230</volume>:<fpage>174</fpage>–<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1002/path.4186</pub-id> <?supplied-pmid 23447416?><pub-id pub-id-type="pmid">23447416</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref038"><text><SENT sid="50630" pm="."><plain><label>38</label><mixed-citation publication-type="journal"><name><surname>Ross</surname><given-names>JS</given-names></name>, <name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Al-Rohil</surname><given-names>RN</given-names></name>, <name><surname>Nazeer</surname><given-names>T</given-names></name>, <name><surname>Sheehan</surname><given-names>CE</given-names></name>, <name><surname>Stephens</surname><given-names>PJ</given-names></name>, <etal>et al</etal> <article-title>Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy</article-title>. <source>Mod Pathol</source> <year>2014</year>;<volume>27</volume>:<fpage>271</fpage>–<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.2013.135</pub-id> <?supplied-pmid 23887298?><pub-id pub-id-type="pmid">23887298</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref039"><text><SENT sid="50631" pm="."><plain><label>39</label><mixed-citation publication-type="journal"><name><surname>Rieger-Christ</surname><given-names>KM</given-names></name>, <name><surname>Mourtzinos</surname><given-names>A</given-names></name>, <name><surname>Lee</surname><given-names>PJ</given-names></name>, <name><surname>Zagha</surname><given-names>RM</given-names></name>, <name><surname>Cain</surname><given-names>J</given-names></name>, <name><surname>Summerhayes</surname><given-names>IC</given-names></name>, <etal>et al</etal> <article-title>Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection</article-title>. <source>Cancer</source> <year>2003</year>;<volume>98</volume>:<fpage>737</fpage>–<lpage>744</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.11536</pub-id> <?supplied-pmid 12910517?><pub-id pub-id-type="pmid">12910517</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref040"><text><SENT sid="50632" pm="."><plain><label>40</label><mixed-citation publication-type="journal"><name><surname>van Rhijn</surname><given-names>BW</given-names></name>, <name><surname>van der Kwast</surname><given-names>TH</given-names></name>, <name><surname>Vis</surname><given-names>AN</given-names></name>, <name><surname>Kirkels</surname><given-names>WJ</given-names></name>, <name><surname>Boevé</surname><given-names>ER</given-names></name>, <name><surname>Zwarthoff</surname><given-names>EC</given-names></name>, <etal>et al</etal> <article-title>FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma</article-title>. <source>Cancer Res</source> <year>2004</year>;<volume>64</volume>:<fpage>1911</fpage>–<lpage>1914</lpage>. <?supplied-pmid 15026322?><pub-id pub-id-type="pmid">15026322</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref041"><text><SENT sid="50633" pm="."><plain><label>41</label><mixed-citation publication-type="journal"><name><surname>Bakkar</surname><given-names>AA</given-names></name>, <name><surname>Wallerand</surname><given-names>H</given-names></name>, <name><surname>Radvanyi</surname><given-names>F</given-names></name>, <name><surname>Lahaye</surname><given-names>JB</given-names></name>, <name><surname>Pissard</surname><given-names>S</given-names></name>, <name><surname>de Medina</surname><given-names>SG</given-names></name>, <etal>et al</etal> <article-title>FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder</article-title>. <source>Cancer Res</source> <year>2003</year>;<volume>63</volume>:<fpage>8108</fpage>–<lpage>8112</lpage>. <?supplied-pmid 14678961?><pub-id pub-id-type="pmid">14678961</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref042"><text><SENT sid="50634" pm="."><plain><label>42</label><mixed-citation publication-type="journal"><name><surname>Al-Ahmadie</surname><given-names>HA</given-names></name>, <name><surname>Iyer</surname><given-names>G</given-names></name>, <name><surname>Janakiraman</surname><given-names>M</given-names></name>, <name><surname>Lin</surname><given-names>O</given-names></name>, <name><surname>Heguy</surname><given-names>A</given-names></name>, <name><surname>Tickoo</surname><given-names>SK</given-names></name>, <etal>et al</etal> <article-title>Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma</article-title>. <source>J Pathol</source> <year>2011</year>;<volume>224</volume>:<fpage>270</fpage>–<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1002/path.2892</pub-id> <?supplied-pmid 21547910?><pub-id pub-id-type="pmid">21547910</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref043"><text><SENT sid="50635" pm="."><plain><label>43</label><mixed-citation publication-type="journal"><name><surname>Billerey</surname><given-names>C</given-names></name>, <name><surname>Chopin</surname><given-names>D</given-names></name>, <name><surname>Aubriot-Lorton</surname><given-names>MH</given-names></name>, <name><surname>Ricol</surname><given-names>D</given-names></name>, <name><surname>Gil Diez de Medina</surname><given-names>S</given-names></name>, <name><surname>Van Rhijn</surname><given-names>B</given-names></name>, <name><surname>Bralet</surname><given-names>MP</given-names></name>, <etal>et al</etal> <article-title>Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors</article-title>. <source>Am J Pathol</source> <year>2001</year>;<volume>158</volume>:<fpage>1955</fpage>–<lpage>1959</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)64665-2</pub-id> <?supplied-pmid 11395371?><pub-id pub-id-type="pmid">11395371</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref044"><text><SENT sid="50636" pm="."><plain><label>44</label><mixed-citation publication-type="journal"><name><surname>Kimura</surname><given-names>T</given-names></name>, <name><surname>Suzuki</surname><given-names>H</given-names></name>, <name><surname>Ohashi</surname><given-names>T</given-names></name>, <name><surname>Asano</surname><given-names>K</given-names></name>, <name><surname>Kiyota</surname><given-names>H</given-names></name>, <name><surname>Eto</surname><given-names>Y</given-names></name>, <etal>et al</etal> <article-title>The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas</article-title>. <source>Cancer</source> <year>2001</year>;<volume>92</volume>:<fpage>2555</fpage>–<lpage>2561</lpage>. <?supplied-pmid 11745189?><pub-id pub-id-type="pmid">11745189</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref045"><text><SENT sid="50637" pm="."><plain><label>45</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>G</given-names></name>, <name><surname>Sun</surname><given-names>X</given-names></name>, <name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Wu</surname><given-names>S</given-names></name>, <name><surname>Huang</surname><given-names>P</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <etal>et al</etal> <article-title>Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation</article-title>. <source>Nat Genet</source> <year>2013</year>;<volume>45</volume>:<fpage>1459</fpage>–<lpage>1463</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2798</pub-id> <?supplied-pmid 24121792?><pub-id pub-id-type="pmid">24121792</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref046"><text><SENT sid="50638" pm="."><plain><label>46</label><mixed-citation publication-type="journal"><collab>Cancer Genome Atlas Research Network</collab>. <article-title>Comprehensive molecular characterization of urothelial bladder carcinoma</article-title>. <source>Nature</source> <year>2014</year>;<volume>507</volume>:<fpage>315</fpage>–<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1038/nature12965</pub-id> <?supplied-pmid 24476821?><pub-id pub-id-type="pmid">24476821</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref047"><text><SENT sid="50639" pm="."><plain><label>47</label><mixed-citation publication-type="journal"><name><surname>Smal</surname><given-names>MP</given-names></name>, <name><surname>Rolevich</surname><given-names>AI</given-names></name>, <name><surname>Polyakov</surname><given-names>SL</given-names></name>, <name><surname>Krasny</surname><given-names>SA</given-names></name>, <name><surname>Goncharova</surname><given-names>RI</given-names></name>. <article-title>FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients</article-title>. <source>Exp Oncol</source> <year>2014</year>;<volume>36</volume>:<fpage>246</fpage>–<lpage>251</lpage>. <?supplied-pmid 25537218?><pub-id pub-id-type="pmid">25537218</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref048"><text><SENT sid="50640" pm="."><plain><label>48</label><mixed-citation publication-type="journal"><name><surname>Guancial</surname><given-names>EA</given-names></name>, <name><surname>Werner</surname><given-names>L</given-names></name>, <name><surname>Bellmunt</surname><given-names>J</given-names></name>, <name><surname>Bamias</surname><given-names>A</given-names></name>, <name><surname>Choueiri</surname><given-names>TK</given-names></name>, <name><surname>Ross</surname><given-names>R</given-names></name>, <etal>et al</etal> <article-title>FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder</article-title>. <source>Cancer Med</source> <year>2014</year>;<volume>3</volume>:<fpage>835</fpage>–<lpage>844</lpage>. <pub-id pub-id-type="doi">10.1002/cam4.262</pub-id> <?supplied-pmid 24846059?><pub-id pub-id-type="pmid">24846059</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref049"><text><SENT sid="50641" pm="."><plain><label>49</label><mixed-citation publication-type="journal"><name><surname>Shinmura</surname><given-names>K</given-names></name>, <name><surname>Kato</surname><given-names>H</given-names></name>, <name><surname>Matsuura</surname><given-names>S</given-names></name>, <name><surname>Inoue</surname><given-names>Y</given-names></name>, <name><surname>Igarashi</surname><given-names>H</given-names></name>, <name><surname>Nagura</surname><given-names>K</given-names></name>, <etal>et al</etal> <article-title>A novel somatic FGFR3 mutation in primary lung cancer</article-title>. <source>Oncol Rep</source> <year>2014</year>;<volume>31</volume>:<fpage>1219</fpage>–<lpage>1224</lpage>. <pub-id pub-id-type="doi">10.3892/or.2014.2984</pub-id> <?supplied-pmid 24452392?><pub-id pub-id-type="pmid">24452392</pub-id></mixed-citation> </plain></SENT>
</text></ref><ref id="pone.0165109.ref050"><text><SENT sid="50642" pm="."><plain><label>50</label><mixed-citation publication-type="journal"><name><surname>Nakanishi</surname><given-names>Y</given-names></name>, <name><surname>Akiyama</surname><given-names>N</given-names></name>, <name><surname>Tsukaguchi</surname><given-names>T</given-names></name>, <name><surname>Fujii</surname><given-names>T</given-names></name>, <name><surname>Satoh</surname><given-names>Y</given-names></name>, <name><surname>Ishii</surname><given-names>N</given-names></name>, <etal>et al</etal> <article-title>Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1</article-title>. <source>Mol Cancer Ther</source> <year>2015</year>;<volume>14</volume>:<fpage>704</fpage>–<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0927-T</pub-id> <?supplied-pmid 25589496?><pub-id pub-id-type="pmid">25589496</pub-id></mixed-citation> </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
